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Abstract
Tolerance blocks the expression of autoantibodies, whereas autoimmunity promotes it. How tolerance
breaks and autoantibody production begins, thus, are crucial questions for the understanding and
treatment of autoimmune diseases. Evidence implicates cell death and autoantigen modifications in the
initiation of autoimmune reactions. One form of neutrophil cell death deserves attention because it
occurs as a consequence of neutrophil activation, requires the post-translational modification of histones
and results in the extracellular release of chromatin. The extracellular chromatin incorporates histones in
which arginines have been converted to citrullines by peptidylarginine deiminase IV (PAD4) creating
structures that capture or "trap" bacterial pathogens. Neutrophil extracellular traps (NETs), as these
structures are known, generate an extracellular complex of deiminated histones and bacterial cell
adjuvants. The complex of bacterial antigens and deiminated chromatin may be internalized by host
phagocytes during inflammatory conditions, as arise during bacterial infections or chronic
autoinflammatory disorders. The uptake and processing of deiminated chromatin together with bacterial
adjuvants by phagocytes may induce the presentation of modified histone epitopes and co-stimulation,
thus yielding a powerful stimulus to break tolerance. To test the hypothesis that NETs can lead to
autoimmunity, we measured autoantibodies to deiminated histones in human autoimmune disorders. We
detected autoantibodies to deiminated histones in Felty's syndrome (FS) patients, whereas
autoantibodies from Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA) patients did not
distinguish deiminated from non-deiminated histones. FS autoantibodies colocalized with deiminated
histone H3 in LPS-treated neutrophils suggesting activated neutrophils as the source of autoantigens. In
addition, we identified and characterized deimination of linker histone H1 and found rare autoantibodies
to deiminated H1 in SLE and Sjogren's syndrome patients. We also studied sera of autoimmune lupus
prone mice to determine if they would recognize deiminated histones and found that deimination
represses binding of murine lupus autoantibodies to histones. The inability of immunoglobin from sera of
lupus mice to recognize deiminated histones suggests the presence of effective tolerance to NET
components released during innate neutrophil response to infections. Our finding of antibodies to
deiminated histones in Felty's syndrome supports the idea that tolerance to deiminated histones is
compromised only in exceptional circumstances. Understanding the tolerance mechanism to deiminated
histones and how they are compromised in patients could be useful to design strategies for the
prevention and treatment of many autoimmune disorders.
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ABSTRACT
Tolerance blocks the expression of autoantibodies, whereas autoimmunity
promotes it. How tolerance breaks and autoantibody production begins, thus, are crucial
questions for the understanding and treatment of autoimmune diseases. Evidence
implicates cell death and autoantigen modifications in the initiation of autoimmune
reactions. One form of neutrophil cell death deserves attention because it occurs as a
consequence of neutrophil activation, requires the post-translational modification of
histones and results in the extracellular release of chromatin. The extracellular chromatin
incorporates histones in which arginines have been converted to citrullines by
peptidylarginine deiminase IV (PAD4) creating structures that capture or “trap” bacterial
pathogens. Neutrophil extracellular traps (NETs), as these structures are known, generate
an extracellular complex of deiminated histones and bacterial cell adjuvants. The
complex of bacterial antigens and deiminated chromatin may be internalized by host
phagocytes during inflammatory conditions, as arise during bacterial infections or
chronic autoinflammatory disorders. The uptake and processing of deiminated chromatin
together with bacterial adjuvants by phagocytes may induce the presentation of modified
histone epitopes and co-stimulation, thus yielding a powerful stimulus to break tolerance.
To test the hypothesis that NETs can lead to autoimmunity, we measured
autoantibodies to deiminated histones in human autoimmune disorders. We detected
autoantibodies to deiminated histones in Felty’s syndrome (FS) patients, whereas
autoantibodies from Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis
(RA) patients did not distinguish deiminated from non-deiminated histones. FS
autoantibodies colocalized with deiminated histone H3 in LPS-treated neutrophils
suggesting activated neutrophils as the source of autoantigens. In addition, we identified
and characterized deimination of linker histone H1 and found rare autoantibodies to
deiminated H1 in SLE and Sjogren’s syndrome patients. We also studied sera of
autoimmune lupus prone mice to determine if they would recognize deiminated histones
and found that deimination represses binding of murine lupus autoantibodies to histones.
The inability of immunoglobin from sera of lupus mice to recognize deiminated histones
suggests the presence of effective tolerance to NET components released during innate
neutrophil response to infections. Our finding of antibodies to deiminated histones in
Felty’s syndrome supports the idea that tolerance to deiminated histones is compromised
only in exceptional circumstances. Understanding the tolerance mechanism to
deiminated histones and how they are compromised in patients could be useful to design
strategies for the prevention and treatment of many autoimmune disorders.
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CHAPTER 1.

INTRODUCTION

Autoimmunity
In 1901 Erhlich coined the term “Horror Autotoxicus” to explain “the
unwillingness of the organism to endanger itself by formation of toxic autoantibodies”.
He found that immunizing goats with their own red blood cells (RBCs) did not lead to
any antibody formation (1). Erhlich postulated that autoimmune diseases cannot occur
and lack of immune response against self antigens came to be known as ‘tolerance’.
However, the first autoimmune disorder was reported in 1904, when Donath and
Landsteiner demonstrated that toxic autoantibodies destroy self RBCs in Paroxysmal
Cold Hemoglobinuria (PCH) (2). For the next 50 years, the study of autoimmune
diseases progressed slowly until Rose and Roitt nearly simultaneously published separate
reports on autoimmune thyroiditis. Rose and Witebsky published evidence for the
experimental induction of autoimmune thyroiditis in rabbits (3, 4). About the same time,
Roitt published a report on thyroid-reacting autoantibodies in Hashimoto’s patients (5).
Identification of Hashimoto’s thyroiditis as an autoimmune condition led to acceptance to
the concept of autoimmunity and opened up the search for others.
The acceptance of autoimmunity forced scientists to look at the immune system in
a new light. Burnet explained that immune response (antibody production) results after
engagement and expansion of clones from a cell with a single specificity (Clonal
Selection) (6) and tried to explain tolerance as a result of “deletion” of self reactive
clones from the B cell repertoire. He postulated that autoimmunity results from the
escape of “forbidden” self reacting clones. Cloning of B cells of healthy individuals
revealed that about 76% of early immature B cells express self reactive antibody
receptors (7). Self reactivity of B cell receptors (BCR) progressively decreased as B cell
development progressed. The first check point against self reactivity was observed
during the transition of immature B cells to mature B cells as the frequency of self
reactive antibodies produced falls to about 40% in B cells newly emigrated from the bone
marrow (7). Another checkpoint for getting rid of self reacting specificities was found
during the maturation of newly emigrant B cells to peripheral naïve B cells (7). In
patients with SLE, about 25-50% of naïve B cells express self-recognizing BCR in
contrast to about 5-20% of B cells from healthy individuals (8). Though these
observations tried to explain autoimmunity on the basis of escape of self reacting B cells,
more questions than answers ensued. What role do self-reactive naïve B cells play in
healthy individuals? In what way are these cells different in healthy individuals and
autoimmune patients? How are the cells bearing self-reactive receptors kept in check in
healthy individuals? It follows that various mechanisms contribute to keep the selfreactive lymphocytes in a state of non-responsiveness called “anergy”. Engagement of
lymphocyte receptors by self-antigens without receiving a second signal (from an
activated helper T cells or CD80/86 expressed on APC) promotes desensitization of
receptor for subsequent re-exposure to antigen. Chronic engagement of BCR with selfantigen results in low calcium influx and activation of inhibitory signaling that prevents
activation of B cells (9, 10). Survival and proliferation of B cells on receptor engagement
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is dependent on B cell activating factor (BAFF; also known as BLyS) and self-reacting B
cells have a higher threshold for BAFF signaling and so they are outcompeted by naïve B
cells for survival in lymphoid follicles (11). Many more mechanisms for maintaining
peripheral tolerance have been found (12-14) and force us to think about other
mechanisms by which autoimmune disorders arise. What conditions favor the
engagement and activation of self-reactive B cells leading to the initiation of autoimmune
diseases? Presently, we have some knowledge about factors that contribute to
autoimmunity, yet understanding how autoimmune responses are initiated and
perpetuated is far from clear.
Owing to the self perpetuating nature of autoimmunity in which the targeted
antigen cannot be cleared from the body, autoimmune responses are extremely
destructive. The autoimmune disorders cause extensive morbidity and can sometimes
become life threatening. The chronic morbidity of autoimmune diseases hampers the
normal lifestyle and productivity of millions of affected people. In the past hundred
years, ever since the discovery of the first autoimmune condition, many more disease
states have been identified that have an autoimmune component.
Types of Autoimmune Disorders
Presently, there are around 80 autoimmune diseases known in humans (15). The
prevalence of autoimmune disorders is estimated to be about 5% in the world population
(16, 17). The current classification of autoimmune disorders is based on the organs
involved, the type of lesion, the morbidity and also the type of autoimmune process
involved. Broadly, autoimmune disorders are grouped into organ-specific or systemic
autoimmune disorders. In organ-specific disorders, the autoimmune immune response is
directed against an antigen that is localized to one particular organ. The classical
example of such an organ-specific autoimmune disorder is Hashimoto’s thyroiditis in
which the thyroid gland gradually becomes dysfunctional. Autoantibodies against
thyroid-specific antigens, thyroid peroxidase, thyroglobulin and thyroid stimulating
hormone (TSH) receptor, are found in patients with Hashimoto’s thyroiditis.
Autoantibodies mediate the destruction of the thyroid resulting in hypothyroidism. Other
organ-specific autoimmune disorders include type 1 Diabetes Mellitus (T1D), Graves’
disease and Autoimmune Hemolytic Anemia.
In systemic autoimmunity, the autoimmune response is directed against a target
antigen that is widespread in its distribution. Systemic lupus erythematosus (SLE) is a
prototype of systemic autoimmunity and is characterized by autoantibodies against
double stranded deoxyribonucleic acid (dsDNA), histones and a variety of other nuclear
antigens that are found in every tissue of the body. The main organ systems involved in
SLE are the kidneys, heart, joints, skin, lung, blood vessels and the nervous system.
Other systemic autoimmune disorders are Rheumatoid Arthritis (RA), Sjogren’s
syndrome (SS) and Dermatomyositis. The development of organ-specific or systemic
autoimmunity depends on the autoantigens targeted by the immune system and their
distribution within the body. In some autoimmune conditions, the cells bearing the
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targeted antigen are distributed to all parts of the body by the circulation leading to
widespread disease manifestations. Classic examples of such autoimmune conditions are
the small vessel vasculitides that involve neutrophil antigens and are characterized by the
presence of anti-neutrophilic cytoplasmic antibodies (ANCA). Three subtypes of small
vessel vasculitides are Wegener’s granulomatosis (WG), Churg-Strauss syndrome (CSS)
and microscopic polyangiitis (MPA). All three of them are characterized by severe
inflammation and granuloma formation in the kidney, lungs, upper respiratory tract,
gastrointestinal tract and skin.
In order to provide effective clinical treatment to millions of patients with
autoimmune diseases, it is necessary to understand how and when some self antigens
become targets of the immune response. A better insight into what drives a particular
autoimmune process will help in preventing autoimmune conditions and guide the
development of new treatments.
Proposed Mechanisms for Autoimmunity
Autoimmunity has a complex etiology. Genetics and environmental factors play
roles in the engagement, activation and proliferation of self-antigen specific lymphocytes
resulting in autoimmunity. Several examples of genetic defects predisposing to
autoimmunity have been described. For example, the src-family tyrosine kinase lyn,
which is associated with membrane immunoglobulin (Ig), is essential for B cell signaling,
and defects in lyn signaling may result in B cell activation by self-antigens and
autoimmunity (18). T cells express an inhibitory receptor, cytotoxic T-lymphocyte
antigen (CTLA4) that competes with CD28 for binding to CD80/86 molecules and
transmits inhibitory signals (19). Polymorphisms in CTLA4 gene were found to be
associated with Grave’s disease as well as T1D (20). In one mouse model of T1D a
variation of CTLA4 mRNA splicing resulting in a molecule with reduced ability to
interact with CD80/CD86 ligands were found (20). With development of new biological
techniques for studying autoimmunity, the following mechanisms have been proposed to
influence initiation of autoimmunity.
Genetic Predisposition
Genetic predisposition plays an important role in the development of autoimmune
disorders. Multiple polymorphisms in major histocompability complex (MHC) genes,
the most extensively studied region of human genome, have been found associated with
autoimmune disorders. In human genes encoding MHC molecules are located on the
short arm of chromosome 6 (21). MHC gene loci are segregated into 3 different classes,
with Class 1 including genes for human leukocyte antigens (HLA) A, B and C. Class II
MHC consists of genes for heterodimeric HLA-DR, DP and DQ molecules. Many other
gene products including complement components (eg C4), tumor necrosis factor alpha
(TNF-α) and heat shock protein 70 (hsp70) are grouped together in MHC Class III (22).
With genes involved in signaling, cell death and antigen processing and presentation
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closely clustered in one small region of the genome, polymorphisms in MHC molecules
influence immunoreactivity against many self antigens. As early as the seventh decade of
the 20th century, association of HLA-B27 with ankylosing spondyloarthopathy (AS) was
established (23, 24). The association of HLA-B27 or its subtypes with AS holds true
worldwide with higher prevalence of AS in populations with higher frequency of HLAB27 (25). Even after this close association between AS and HLA-B27, a genetic study
found that only 16% of identical twins with HLA-B27 positive genotype developed AS
(26). More recently, it was found that susceptibility to AS is not limited to HLA-B27
haplotypes, but extends to other Class I and Class II MHC molecules including A2, A9,
Bw and DR1/DR2 (27). Thus a genetic component is found in almost all patients with
AS, although the HLA haplotype is not the only contributor to the development of AS
because about 90% of HLA-B27 positive individuals remain free of the disease (27).
This suggests that there must be an environmental trigger for AS development.
Nevertheless, the association of AS and HLA-B27 provide a classic example of one
genetic trait conferring susceptibility to disease.
Genetic contributions to autoimmune susceptibility have been identified in almost
all known autoimmune conditions. Recent studies have shown that certain HLA-DR2
and DR3 Class II haplotypes contribute to development of SLE (28). MHC associated
risk factors for SLE are not limited to Class II haplotypes but extend to involve the Class
III region also particularly in superkiller viralicidic activity 2-like (SKIV2L), tumor
necrosis factor (TNF) and complement component C4 gene loci regions (29, 30).
Genetic as well as animal model studies establish that HLA antigens, particularly HLADR and DQ also contribute to autoimmune susceptibility in RA and Type 1 diabetes (3133).
Advanced genetic studies in recent years have located several polymorphisms in
genes outside the MHC cluster that are associated with increased incidence of
autoimmunity. Linkage analysis studies identified polymorphisms associated with signal
transducer and activator of transcription 4 (STAT4) in RA and SLE (34), and nucleotide
binding and oligomerization domain 2 (NOD2) in Crohn’s disease (35, 36). Genomewide association studies, possible after the complete sequencing of human genome,
further enhanced the number of genes associated with autoimmune conditions. Many of
these genes are involved in signaling pathways of T cell (PTPN22)(37) and B cell
(BANK1, BLK)(38-40) development, or in co-stimulation signaling during antigen
presentation (CTLA4, CD40)(41-43). Polymorphisms in genes involved in interferon
production (IRF5, IRF8, IRAK1, and STAT4)(44, 45) and cell to cell communication
(IL-2, IL-12A, IL-23R) (46) may influence T and B cell interaction with self-antigens in
various ways and thus be associated with autoimmune disorders. Even though many
genetic polymorphisms and mutations have been found to associate with autoimmune
disorders, the impact of any one genetic factor on the development of autoimmunity is
very modest. Only a few conditions, such as autoimmune lymphoproliferative syndrome
due to mutations in fas (CD95 or Apo 1) and autoimmune polyglandular endocrinopathy
with candidiasis and ectodermal dysplasia (APECED) that occur due a mutation in the
Autoimmune Regulator (AIRE) gene, are examples of autoimmune disorders arising due
to direct consequence of genetic defects (47, 48). Most of the genetic factors provide
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additional susceptibility in the run up to full blown autoimmune disorders, but their
contribution to initiation of autoimmunity remains unsubstantiated. Involvement of
multiple genetic components in individual autoimmune disorders and also of one genetic
polymorphism in multiple autoimmune conditions points to an input from multiple genes
toward the susceptibility to autoimmunity.
Mouse models of autoimmune disorders have contributed to the understanding of
the complex genetic contribution to autoimmune disorders. Clear evidence of genetic
involvement in autoimmune diseases came from the observation that mice of a certain
genetic background, such as MRL/lpr, (NZB x NZW) F1 and NZM2410 develop
autoimmune conditions mimicking human disease. Study of such mice that
spontaneously develop autoimmunity narrowed the boundary of genetic intervals that
contribute to breaking of tolerance in these animal models of SLE. By backcrossing
NZM2410 mice to C57BL/6 mice 3 genetic intervals named Sle1, Sle2 and Sle3 were
identified that contribute to disease susceptibility (49). By segregating these
susceptibility loci on a non-autoimmune background important insights in the
mechanisms by which they promote autoimmunity was gained. It was found that Sle1
locus predisposes for autoantibody production against nuclear antigens (49, 50). Genes
in the Sle2 interval lower the activation threshold of B cells, resulting in a higher
production of polyclonal IgM, but not of IgG antibodies (49, 51). B cells from mice
harboring the Sle2 locus were hyperresponsive to antigen challenge suggesting that this
locus may contain a gene that reduces the threshold for B cell activation (51). While Sle1
and Sle2 loci influenced the effector B and T cells, the Sle3 locus on chromosome 7
predisposed to autoimmunity by increasing antigen presentation by dendritic cells (52).
The antigen presenting cells from mice bearing the Sle3 locus, were more efficient at
presenting antigens to T cells and releasing more proinflammatory cytokines as compared
to APCs from normal mice (53). Though these congenic mice models have helped in
understanding the role each of these genetic intervals play in autoimmunity, the actual
process by which autoimmunity is initiated is far from clear.
One problem in understanding the mechanisms of autoimmunity as a result of
only genetic contribution is that at times one gene may predispose to many autoimmune
conditions: PTPN22, a gene involved in B and T cell signaling is associated with
autoimmune thyroiditis, RA, SLE and T1D (54). STAT4 which regulates INF gamma
production is involved both in SLE and RA (55). Different manifestations of a single
gene defect point to additional factors involved in the etiology of autoimmune disorders
over and above the genetic elements that predispose to autoimmunity. Though an
underlying genetic background favors the development of autoimmunity, disease
manifestations may differ as they reflect differences in the underlying mechanisms of
autoimmunity. These observations coupled with the fact that not every individual
inheriting disease associated genotypes eventually develops autoimmunity suggest that
multiple factors, in addition to genetics, are involved in the initiation and progression of
an autoimmune response. Presently, it is believed that different genetic factors lower the
threshold of an individual for breaking tolerance but the initiation of an autoimmune
response needs an additional trigger. It is obvious that in addition to predisposing genetic
factors, environmental influences contribute to overt autoimmunity.
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Environmental Factors in Autoimmunity
Several environmental toxins and infectious agents are associated with
autoimmune disorders. Classical involvement of infections in initiating an autoimmune
response is seen in rheumatic fever associated carditis and Guillian-Barre Syndrome
(GBS) associated polyneuropathy (56). In rheumatic fever, the immune response against
the M protein of Streptococcus pyogenes cross reacts with myosin from cardiac
myocytes, thus leading to myocarditis (57, 58). A common event that preceeds GBS is
infectious diarrhea caused by Campylobacter jejuni, suggesting infection with C.jejuni as
a predisposing condition for GBS. Viral infections as well as vaccination against
influenza virus have also precipitated GBS, clearly pointing to the role of infections in
initiating this autoimmune myelitis (59). Definite mechanisms by which infections result
in GBS are not known, but it is assumed that immune response against a pathogen later
re-directs itself against antigens on gangliocytes. This type of cross reactivity is similar
to the crossreactivity shown by M protein of S. pyogenes and antigens on cardiac
myocytes in rheumatic fever. The cross reactivity is thought to arise from “molecular
mimicry” between antigens expressed on pathogen and host tissue. Several other
infections agents are thought to promote autoimmunity. Epstein-Barr virus (EBV) is
associated with systemic lupus and in a study it was noticed that SLE patients develop
antibodies to EBV protein EBNA-1 prior to developing autoantibodies (60). It is found
that antibodies to EBNA-1 cross react with self-antigen Ro, one of the many autoantigens
targeted by autoantibodies (61). Molecular mimicry has been postulated to be a
mechanism by which infections can cause autoimmune diseases (62, 63).
The environment may influence autoimmunity in ways other than infections.
Exposure to chemical substances can also promote autoimmunity. Mice exposed to
environmental toxins such as mercury or demethylating agents, procainamide or
hydralazine develop an autoimmune response similar to that seen in SLE. The
“molecular mimicry” hypothesis does not provide an explanation for chemical-induced
autoimmunity and the mechanism remains poorly understood. One possible explanation
is that chemicals induce covalent modifications in the host antigens that cause the
immune system to recognize modified self antigens in a manner such that an immune
response occurs.
Post Translational Modification of Proteins: Generation of “Neo-epitopes”
Post translational modifications (PTM) play an important role in various cellular
functions ranging from cell division to cell death by rapidly altering protein structure,
function and interactions with other proteins. While doing so PTMs might also change
the way the immune system recognizes a particular protein by generating “NeoEpitopes”. A neo-epitope is a portion of a protein that gets modified in a manner such
that recognition by a lymphocyte antigen receptor is also altered. PTMs are one way neoepitope can arise. Tolerance to neo-epitopes has not been established during lymphocyte
development. Such “neo-epitopes” may activate lymphocytes in a similar manner as
foreign antigens.
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A variety of PTM including phosphorylation, acetylation, glycosylation,
methylation and deimination have been identified on autoantigens (64, 65). Importantly,
several of these modified autoantigens are preferentially processed, presented and
recognized by the immune system contributing to the development of autoimmunity (66,
67). PTMs associated with apoptotic cell death increase the immunogenicity of self
antigens and predispose to autoimmunity. Examples of apoptosis-related PTMs include
phosphorylation, acetylation, ubiquitination and transgluamination of histones (68).
Phosphorylation of small nuclear ribonucleoprotein (snRNP) (U1-70K) and acetylation of
histone H4 (H4-8K) cause enhanced immunoreactivity with systemic lupus sera (69, 70).
PTMs contributing to autoimmune disease are not limited to nuclear self-antigens.
Hydroxylation and glycosylation of collagen result in severe disease manifestations in a
collagen-induced mouse model of arthritis (71, 72). In addition, deiminated proteins are
targets of autoantibodies in RA (73). The high specificity and sensitivity of antideiminated protein antibodies in RA led to the development of several diagnostic kits
(74). Although the preferential recognition of PTMs by autoimmune sera supports the
“neo-epitope” theory for initiation of autoimmunity, the lack of reactivity to these PTM
in control subjects argues for effective tolerance mechanisms. So how and when these
PTM affect the development of autoimmune disorders is still an open question.
Cell Death, Exposure of Hidden Antigens and Defective Clearance
The involvement of dead cell remnants in the etiology of autoimmunity was
reported in 1943 by Hargraves et al. who showed that dead polymorphonuclear (PMN)
leucocytes are responsible for the LE cell phenomenon (75). They found that PMNs
from the bone marrow of SLE patients have phagocytosed free nuclear material that
appeared to be partially “lysed,” “digested” or “decondensed”. This was in contrast to
the phagocytosis of nuclear material observed in the “Tart” cells from healthy individuals
that retain all the characteristic of nuclear staining. The degenerated nuclear material of
LE cells attracted PMNs, to form rosettes. They also observed that the chemotactic
attractiveness of the nuclear material was lost once it was been engulfed by the PMNs.
These were the first observations to suggest that the exposure of nuclear remnants and
defective clearance may constitute mechanisms for the development of autoimmunity.
Haserick and Bortz found that a plasma factor, immunoglobulin, was responsible for the
LE cell phenomenon (76). This heralded the discovery of a plethora of autoantibodies
against the nucleus and its components (anti nuclear, anti-DNA and anti histone
autoantibodies) that are found commonly in SLE patients. Although, the mechanism for
the induction of these autoantibodies is not completely understood, there is evidence that
membrane disintegration following cell death might make these autoantigens accessible
(77-81). In accordance with this view, increased apoptotic rates for lymphocytes were
observed in patients with SLE and other autoimmune disorders (82). This raises
important questions like whether it is the excessive cell death in SLE which predisposes
for autoimmunity. Or is the increased apoptosis seen in SLE patients a consequence of
an underlying autoimmune disease process?
Evidence so far suggests that both of the above possibilities are true to some
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extent. Apoptotic mechanisms not only expose nuclear and other potential autoantigens
but also enhance the immunogenicity of these autoantigens by subjecting them to various
PTMs and enzyme action (83-85). Caspases, the main effectors for apoptosis, also
facilitate the translocation of nuclear autoantigens to cytoplasm by cleaving the nuclear
localizing signal of various proteins (86) and allow the development of apoptotic surface
blebs by activating ROCK1 kinase (81, 87, 88). With these studies, it became clear that
apoptotic cells are involved in making nuclear autoantigens available to react with B cells
or other APC. This however doesn’t explain the mechanism for the initiation of the
autoimmune response. A big question remains: if potential autoantigens are expressed on
cells undergoing apoptosis then why do not all individuals develop an autoimmune
response at some point of time?
Excessive cell death or defects in the clearance of dead cells also predispose to
autoimmunity, as implied by studies of knock-out mice lacking genes involved in
clearance or regulation of apoptosis (89). One of the first clues indicating that
autoimmunity arises from clearance defects was provided by C1q deficient mice that
developed autoimmunity resembling SLE, including immune complex deposition and
accumulation of apoptotic bodies in the glomeruli (90). Similarly, animals defective for
other molecules involved in the clearance of dead cells such as Mer tyrosine kinase (91,
92) or milk fat globule E8 (MFG-E8) (93) developed high titres of autoantibodies and
glomerulonephritis. Clearance defects are also found in SLE patients. Macrophages
derived from circulating monocytes of SLE patients are small, have impaired function
and die earlier than those derived from control subjects (94). Nuclear remnants of dead
cells were also found to be associated with follicular dendritic cells (FDC) in the
germinal center in patients with SLE (95). This highlights the defective clearance
mechanisms that are prevalent in SLE patients, and links them to the persistent antinuclear B cell activation that characterizes SLE.
Though it became clear that effective clearance of dead cells is necessary for
avoiding autoimmunity, researchers soon discovered that an absence of factors involved
in clearing dead cells does not always lead to autoimmunity. The strongest association
between autoimmunity and dead cell clearance is observed in C1q deficiency. Yet, a
specific mixed genetic background - (129/O1a X C57BL/6)F2 was needed in C1q
knockout mice to develop autoimmunity (90). This may be due to the redundancy of
mechanisms involved in clearing dead cells and may suggest that additional mechanisms
are involved in developing the manifestations of an autoimmune phenotype. Dead cell
membranes lose their phospholipid asymmetry leading to the exposure of anionic
phospholipids such as phosphotidylserine (PS). The exposed PS can be recognized by a
number of phagocytic scavenger receptors (96) as well as many freely circulating
opsonins like T-cell immunoglobulin mucin (Tim-1, Tim-4) (97), MFG-E8 (98) and
Protein S (99). This redundancy means that the deficiency of one component of a
clearance system can be tolerated well. Also apart from specialized phagocytic cells,
such as macrophages, dead cells can be taken up and cleared by epithelial, endothelial
and fibroblastic cells (100-105).
The role of apoptosis in the initiation of autoimmunity came into question when it
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was found that apoptotic cells promote secretion of anti-inflammatory factors such as IL10 and TGF-β from resident dendritic cells. This increases the rate of dead cell clearance
while maintaining immune unresponsiveness (106, 107). Moreover, macrophages
encountering apoptotic cells respond in an anti-inflammatory and immunosuppressive
way (108, 109). Apoptotic cells inhibit the activation of macrophages by inducing
production of TGF-β, prostaglandin E2 (PGE2) and platelet activating factor (PAF)
(109). While mechanisms involved in all anti-inflammatory mediator release are not
fully understood, TGF-β secretion appears to depend on PS recognition (110). In
addition to the indirect suppression of macrophage activation by TGF-β and IL-10, direct
recognition of apoptotic cells by the c-mer proto-oncogene receptor tyrosine kinase (MerTK) inhibits toll like receptors (TLR) signaling by upregulating the production of
suppressor of cytokine synthesis (SOCS) proteins (111). Moreover, monocytes incubated
with apoptotic cells produced IL-10 in response to lipopolysaccharide (LPS) treatment
indicating the dominant immunosuppression mediated by apoptotic cells (112).
Apoptotic cells also suppress TNF-α secretion by epithelial cells in response to LPS
(104). The immunosuppression by apoptotic cells can be mediated by a rapid
transcriptional repression of inflammatory cytokines (113, 114) as well as by the
inhibition of extracellular signal-regulated kinases 1 and 2 (ERK1/2) (115).
These observations, together with the fact that apoptosis is an ongoing process
that is essential in development, raised the possibility that different cell death pathways
elicit varied responses from the immune system. In support of this, it was shown that
necrotic cells induce the production of proinflammatory cytokines by engaging TLRs
(116). The plasma membrane damage in necrotic cells results in leakage of molecules
that can be recognized by pattern recognition receptors (PRR). Many of these “danger”
molecules (e.g. HMGB1) are capable of promoting inflammation by engaging TLRs
(117). The involvement of these endogenous molecules supports the danger model of
immune activation (118). Necrosis occurs commonly as a consequence of an external
insult such as infections. The danger molecules, together with pathogen associated
molecular patterns (PAMPs) associated with infectious agents are capable of stimulating
the production of proinflammatory molecules. Thus, innate immune responses provide
suitable conditions for initiation of an adaptive immune response. It is likely that the
presence of self antigens in proinflammatory conditions, such as arise during infection,
may predispose for the development of adaptive autoimmunity.
Autoimmunity: Interplay of Innate and Adaptive Immunity
Autoimmunity by definition is the immune response against self antigens that are
recognized as if they were “foreign”. In understanding autoimmunity a lot can be
inferred from the way the immune system reacts against infectious agents. After an
infectious agent has breached the cellular integrity of host, the damaged cells of the host
alarm the locally residing macrophages to a foreign intrusion. Soluble (complement,
IgM), cell surface expressed (TLR 1,2,4,5 &6), endosomal (TLR 7,8,&9), and
cytoplasmic (NOD like receptors) PRRs recognize PAMPs that are evolutionarily
conserved on infectious agents and prepare for a response against invading agent. The
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response usually consist of local infiltration by cells of innate immune system that are
capable of responding to infection as well as preparing for the presentation of foreign
antigens to the adaptive immune system for a vigorous and more focused response.
Immune Response to Infectious Agents and Lessons for Autoimmunity
As soon as the infectious agent or host cell damage is identified, surrounding
endothelial and stromal cells release numerous cytokines such as IL-1β, IL-8, IL-18,
IL-25, IL-33 (119) as well as several alarmins such as HMGB1, heat shock protein (HSP)
and uric acid (120, 121) that activate locally residing macrophages, recruit monocytes
and neutrophils from intravascular space into the extravascular site of inflammation and
promote activation of B and T cells. Macrophages and monocytic cells recruited at the
site of infection are capable recognizing PAMPs and and are primed to phagocytose and
kill extracellular pathogens. If infection cannot be brought under control by these
mechanisms, these cells also promote processing and presentation of antigens to T cells
that influx into the site of inflammation. Antigens from previously unencountered
pathogens are engaged by B and T cells with assistance initially from macrophages and
later by dendritic cells (122). T cells so activated further help antigen specific B cells to
differentiate into antibody producing plasma cells and long lived memory B cells
completing the recruitment of the adaptive arm of immunity to fight invading infection
(123). If B and T cells have responded to the pathogen earlier and have generated
memory cells, an effective adaptive immunity mounts quickly. In this manner, the innate
immune system not only fights against the invading pathogen, but also facilitates the
activation of the adaptive arm of immunity (124).
What lessons can be learnt from pathogen-immune system interactions that can
help us understand autoimmunity? It can be easily deduced that adaptive autoimmune
immune responses in a local inflammatory environment will follow an activation course
potentially involving autoantigens that will be similar to that against foreign infectious
agents. After encountering antigens B cells undergo somatic hypermutations and affinity
maturation so as to produce more specific antibody response (125). Similarly, antibodies
from patients with autoimmune diseases show characteristics of hypermutation and
affinity maturation suggesting that autoimmunity is an antigen driven process (126).
Two fundamental differences that separate autoantigens from antigens of foreign
infectious agents are “inaccessibility” as most autoantigens are within membrane
compartments and “lack of inflammation” at least in the initial phase. In circumstances
such as cell death there is large expression of hidden autoantigens that can be equated to
the initial inoculation by an invading pathogen. If activation of innate immune response
occurs simultaneously the result can be development of autoimmune response against
self-antigens.
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Successful Adaptive Immune Response Requires Contribution from Innate
Immunity
Previously considered as two separate branches of immunity, it is now evident
that innate and adaptive components of immune system interact and intricately influence
the activation of each other so as to offer comprehensive protection against foreign
antigens. Various PRRs on cells of the innate immune system (e.g. dendritic cells,
macrophages) are instrumental in directing the T cell responses by increasing the
presentation of peptide MHC complex as well as upregulation of co-stimulatory
molecules (127, 128). Engagement of BCR with an antigen together with the interaction
of its CD40 molecules with CD40L expressed on activated CD4+ helper T cells promotes
B cell clonal expansion and differentiation into short lived plasma cells. B cell interaction
with helper T cells also promotes class switch recombination of BCR receptor and
affinity maturation, migration, and transition into memory cells and long lived plasma
cells (129). The role of innate immunity in facilitating B cell immunity against antigen
does not stop to just promoting helper T cell activation. Certain populations of dendritic
cells (CD11clo ) promote activation and proliferation of Marginal Zone B cells (MZ B
cells) and B1 B cells against antigens in a T cell independent manner(130).
T independent B cell responses are mediated by the release of BAFF and a proliferation
inducing ligand (APRIL) secreted by activated dendritic cells, macrophages and
neutrophils (130, 131). It is not just the innate immune system that feeds into the
adaptive immune system. Antigen specific antibodies from B cells promote clearance of
opsonized antigens through Fc receptor mediated phagocytosis (132). Also activated
T cells secrete cytokines that promote activation and maturation of macrophages and
dendritic cells.
Components of Innate Immunity Involved in Autoimmunity and Tolerance
Processing and presentation of antigens are not limited to foreign or infectious
agents. Dendritic cells were found to take up and process self antigens, especially from
dying cells (133-135). Then how is tolerance maintained against self antigens? It
follows that in the absence of inflammation uptake of self antigens, mostly from
apoptotic cells, is done without maturation of dendritic cells. These immature dendritic
cells express low levels of MHC-peptide complex and are devoid of co-stimulatory
molecules (136). In case of infectious agents, engagement of TLRs by PAMP of
infectious agents induces maturation of dendritic cells (136). Maturation of dendritic
cells results in increased secretion of inflammatory chemokines (137), cytokines (138) as
well as several growth factors (IL-2) needed for T cell maturation (139). Formation of
peptide-MHC complexes is increased (140) along with the expression of co-stimulatory
molecules that results in T cell activation. Interaction of self-antigens with immature
dendritic cells devoid of co-stimulatory signals results in deletion or anergy of self
specific T cells (141, 142). Are mature dentritic cells that express co-stimulatory
molecules capable of initiating an immune response against self antigens? With an
elegant study, Probst et al found that presentation of LCMV derived peptides by steady
state immature dendritic cells induced T cell anergy whereas those presented by mature
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and activated dendritic cells promoted an immune response (143). This supports the idea
of PAMP or endogenous TLR ligand engagement by dendritic cells promoting
autoimmune T cell response against self-antigen. Though specific challenge of mice
transgenic for ovalbumin expression in pancreas with various TLR ligands failed to
induce autoimmunity (144) indicating that perhaps local inflammatory environment is
needed for successful presentation of self-antigens.
Both murine and human B cells express TLRs including TLR1, TLR2, TLR7,
TLR9 and TLR10 (145) which can be activated by various PAMPs and even with some
endogenous ligands. B1 and MZ B cells are particularly responsive to TLR mediated
maturation, proliferation and differentiation into plasma cells that is independent of T cell
help (146). Nuclear autoantigens associated with RNA or DNA can activate autoreactive
B cells by TLR7/TLR9 engagement by providing the required second signal after BCR
engagement and so promoting autoantibody production without T cell help (147, 148).
An example of this can be seen in activation of rheumatoid factor producing B cells with
endogenous DNA of immune complexes acting through simultaneous BCR and TLR
engagement (148). Thus, activation of innate immunity can promote autoimmune
responses from B cells by direct activation of TLRs expressed on B cells or indirectly by
promoting activation of APCs. Infections increase host cell death and promote activation
of innate immune system by engaging various PRRs and thus provide a unique example
by which activation of innate immunity can proceed to development of autoimmunity.
Several endogenous TLR ligands like fibrinogen, hyaluronate, heat shock proteins and
modified low density lipoproteins have been identified as capable of activating B cells by
engaging TLR receptors (149).
Infections Generate an Environment Suitable for Autoimmunity
For a long time, infections have been thought to contribute to the development of
autoimmunity. Many autoimmune conditions like GBS or autoimmune carditis arise after
a bout with infection. In many chronic autoimmune conditions such as SLE and RA,
infections cause flairs and worsening of symptoms. There are multiple mechanisms by
which infectious agents may contribute to autoimmunity.
Molecular Mimicry
Molecular mimicry suggests that some pathogens carry epitopes similar to host
molecules and that these may be responsible for the development of autoimmunity. The
similarity in amino acid sequence or structure between host and infectious molecules can
cause the immune response against infectious agent to cross react with self. Molecular
mimicry, as a mechanism of autoimmunity is most studied in cardiac autoimmune
conditions. Acute cardiomyopathy of rheumatic fever after group A streptococcal
pharyngitis is a classical example of molecular mimicry related autoimmunity.
Monoclonal antibodies developed from the B cells of patients with acute rheumatic fever
with streptococcal pharyngitis cross react with both streptococcal M protein and also with
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cardiac myosin (150). CD4+ and CD8+ T cells isolated from a patient with rheumatic
carditis have shown cross reactivity to both recombinant myosin M protein and human
cardiac myosin, laminin and tropomyosin (151). Molecular mimicry is also seen between
Coxsackievirus B (CVB) and cardiac myosin (152). It was suggested that the immune
response arising against CVB3 virus cross reacts to myosin to cause myocarditis (153).
In another example of molecular mimicry being involved in the development of an
autoimmune disease in humans, it was found that LPS derived from C.jejuni serotypes
that predispose to GBS resembles human ganglioside structure (154, 155). Immunization
of rabbits with C. jejuni LPS caused development of flaccid paralysis similar to that seen
in human GBS patients. Affected rabbits also developed antibodies against GM1
ganglioside (156). Though many such examples of cross reactivity between infectious
agents and host tissue exist, molecular mimicry fails to provide an easy explanation for
the development of autoimmunity. The majority of individuals who get infected with C.
jejuni do not develop flaccid paralysis. Therefore, multiple factors from both host and
infectious agents must be responsible for determining whether an episode of infection
will result in autoimmunity.
Bystander Activation and Epitope Spreading
Immature APCs maintain peripheral tolerance by continuously presenting self
antigens to naïve T cells in absence of costimulatory molecules (157). Such engagement
without costimulatory signalling results in T cell anergy. In an inflammatory
environment, APCs upregulate CD80/CD86 costimulatory molecules while presenting
foreign derived peptides to antigen specific T cells. APCs also secrete generous amounts
of cytokines (IL-2, TNF-α and IL-6) which can activate nearby naïve T cells with other
antigen specificities independent of TCR engagement in a phenomenon called “bystander
activation” (158, 159).
Self reactive T cells thus can get activated to respond against self antigens in an
inflammatory environment. Good examples of bystander activation leading to
autoimmune disorders are provided by T1D and Multiple Sclerosis (MS). In both these
diseases the concordance rates in monozygotic twins are approximately 40%, indicating
an environmental link to the development of autoimmunity (160-162). Rubella, mumps,
CVB4 and Cytomegalovirus (CMV) infections are found to associate with T1D and
antibodies against pancreatic islets are found in rubella (163) and CMV (164) infected
patients. Many children get rubella and mumps early in life and protective antibodies
against the two persists nearly for life. As the majority of these kids do not develop
diabetes, molecular mimicry by itself does not explain the association between these viral
infections and T1D. Though the exact mechanism by which different viruses can cause
T1D is not fully understood, bystander activation of self-reactive T cell clones is likely to
be involved. One study found that preexisting autoreactive T cells are needed for
acceleration of disease in the CVB4-infected NOD mouse, thus implying that the
accelerated disease manifestation is the effect of bystander activation rather than CVB4
infection induced direct damage of the pancreas (165). Viral (and many bacterial)
components can induce the release of inflammatory cytokines and up regulation of MHC
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class I and class II molecules on cells. In Theiler’s murine encephalomyelitis virus
(TMEV) induced model of MS, the reactivity against myelin epitopes does not arise due
to molecular mimicry between the virus and myelin sheath. Instead, there is a temporal
progression of anti-myelin reactivity from an immunodominant myelin epitope to other
myelin components and blocking of costimulatory B7 CD27 prevents the onset of chronic
autoimmune demyelination (166). The TMEV model of MS also gives a good example
of epitope spreading, where the immune response slowly progresses from
immunodominant epitope of myelin to other non immunodominant components.
Persistance of viral RNA during this time suggests bystander activation as mechanism
responsible for initiation of antimyelin autoimmunity.
Cryptic Antigens and Epitopes
Self antigens commonly associated with autoimmune disorders are usually hidden
inside cell membranes. Most notable of these are the nuclear antigens. This has led to
the hypothesis that autoimmunity arises when these membrane bound or cryptic antigens
become exposed to circulating T/B cells. Cell death provides circumstances where
nuclear antigens become exposed at the cell surface (80). Infections cause massive cell
death as well as result in the influx of neutrophils, monocytes and lymphocytes. Thus
infections provide an environment where self ignorant, non-tolerant immune cells can be
activated while encountering cryptic self antigens. While this seems a simple and likely
explanation for the initiation of autoimmunity against organ specific or cell sequestered
cryptic self antigens, it has been found that organisms have mechanisms to avoid
“immunological ignorance” during T cell development (167). With the mediation of
AIRE (autoimmune regulator of gene expression) in the thymus, several organ specific
antigens are expressed in the medullary region of thymus so that even organ-specific self
reactive T cells can be eliminated from the peripheral repertoire (167). This greatly
decreases and often eliminates the risk of autoimmunity towards self antigens expressed
in organ specific locations. Because self reactive T cells are known to exist in the
periphery, it can be assumed that infections can still contribute to the development of
autoimmunity by inducing cell death and providing an excess of cryptic self-antigens.
Crypticity is not only associated with antigens, but also with certain epitopes
within self antigens. Certain (cryptic) portions of an antigen are not recognized by T
cells, whereas other immunodominant portions are easily recognized. This is clearly
evident from studies of proteolipid protein (PLP), an autoantigen in MS. Epitope
mapping studies using overlapping peptides and PLP-specific T cells from MS patients
revealed two immunodominant peptides (p30-49, p180-199) such that T cell lines
generated using these two peptides responded well to intact PLP. However, other T cells
responded to different PLP peptides (p80-99, p90-109, p170-189, p260-276) but not to
intact PLP (168). Even in the case of acetylcholine receptor (AChR), three peptides
(p75-115, p138-167 and p309-344) generated T cell lines but these T cells did not
respond to either full length or fragments of the AChR alpha chain. Interestingly one
p309-344 specific T cell line responded to a trypsin treated AChR fragment (p256-366)
but not to the untreated fragment (169). This gives an example of how differential
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processing of antigen by proteases can unmask cryptic epitopes on self antigens and
influence the generation of immune response against self antigens. These studies
however don’t implicate cryptic epitopes in the etiology of autoimmune disease, as
proliferation of T cells in response to peptides can be viewed as an in vitro artifact.
Evidence that cryptic epitopes are important in manifestation of autoimmune diseases
comes from Lewis rat models of uveoretinitis where disease can be induced by
immunizing rats with bovine interphotoreceptor retinoid binding protein (IRBP). Apart
from the full protein, the disease was also induced by immunizing rats with cryptic
peptides (170) or by transferring cryptic epitope-specific T cells (171). The importance
of antigen processing by APC in the response against cryptic peptides became evident as
T cells lines against one of the epitopes (p1158-1180) responded to IRBP treated with
endopeptidases but not against intact IRBP. Effect of antigen processing or presentation
on generation of cryptic peptides involved in autoimmunity is also observed when
myocarditis resulted in Lewis rats by immunization with trypsin-digested but not intact,
untreated porcine cardiac myosin (172).
Immunization of B10.BR mice with cryptic epitopes (p26-40, p56-70) from the D
protein of small nuclear ribonucleoprotein (snRNP) induced a lupus like syndrome (173).
Similarly a cryptic peptide (p104-117) from myelin proteolipid protein was able to induce
experimental autoimmune encephalomyelitis (EAE) in SJL/J mice when used as an
immunogen (174). Also T cells specific to p104-117 of PLP were able to introduce
disease when adoptively transferred to naïve mice. Splenocytes from SJL/J mice
immunized with whole PLP did not proliferate when incubated with the cryptic p104-117
peptide (174) indicating that this epitope does not result from processing of the native
protein by APCs. The ability of cryptic p104-117 peptide to induce splenocyte
proliferation in an antigen specific manner, when immunized in SJL/J mice, suggests that
lymphocytes recognizing such self-antigen cryptic epitopes may be a part of the normal
repertoire. Events, such as infection or injury, can lead to the unmasking of these cryptic
epitopes for antigen processing and presentation to such self reactive lymphocytes.
Unmasking of cryptic epitopes may occur as a direct consequence of infection as several
infectious agents carry unique proteases. Alternatively, the host response to infection
may activate many proteases. For example, neutrophils enter infected tissues and release
primary, secretory and azurophilic granules rich in various proteases (Elastase, PR3 and
Cathepsin G). They also kill microorganisms by a burst of reactive oxygen species which
can unmask cryptic epitopes by introducing non specific nicks in host proteins.
Moreover, neutrophil activation results in PTM of host proteins that can unmask cryptic
epitopes or generate “neo-epitopes”. Thus, in addition to direct involvement of infectious
agents, innate host responses, such as neutrophil activation, provide conditions for the
activation of self reactive lymphocytes, possibly initiating autoimmune disorders.
Neutrophils: First Line of Defense against Infections
Neutrophils are the first cells to be recruited to the site of inflammation and in
most instances neutrophil responses are sufficient to clear pathogens. Being the frontline
warriors against infection, neutrophils are the most numerous and most reactive immune
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cells in the body. They form about 60-70% of circulating immune cells in human blood
and they enter sites of inflammation in great numbers. Neutrophils employ numerous
mechanisms to capture and kill microorganisms. They can either ingest a pathogen to kill
it by phagocytosis or can release granules with various toxic substances for extracellular
killing.
Neutrophil Engagement of Infectious Agents: Mechanisms and Consequenses
The primary role of neutrophils is to engage and eliminate invading microbial
agents. For this, they employ many effective mechanisms. Neutrophils granules can be
discharged as soon as an invading infectious agent is identified. The first of these
granules to be emptied are the peroxidase negative gelatinase granules (secondary
granules) that contain a variety of matrix metalloprotinases (MMP8, MMP9, MMP25).
These proteases degrade surrounding laminins, collagen, proteoglycans and fibronectin.
Matrix metalloproteinase action is important in degrading the surrounding tissue and
facilitating more neutrophil recruitment. Proteases also help in collapsing the blood and
lymphatic vessels, thus blocking the escape routes for the bacteria and preventing further
colonization. Secondary granules contain a variety of antimicrobial (lactoferrin,
lipocalin, lysozymes) and chemotactic substances such as cathelicidin-LL37. While
lactoferrin and lipocalin starve the bacteria for iron, lysozyme and LL37 are microbicidal
in their own right.
Depending on the infectious agent involved and severity of infection, release of
gelatinase granules is followed by the release of peroxidase-positive azurophilic
(primary) granules. The azurophilic granules contain potent serine proteases: cathepsin
G, neutrophil elastase, protease 3 along with azurocidin/CAP37 and myeloperoxidase
(MPO) (175, 176). Azurocidin/CAP37, a homologue of serine proteases is potently
bactericidal but lacks protease activity (177). Azurocidin is also chemoattractant to
moncytes and macrophages and helps in their recruitment at the site of inflammation
(178). MPO is involved in the production of numerous reactive oxygen species (ROS),
mainly hypochlorous acid, which can react with amines to form bactericidal chloramines
(179). The importance of ROS production by neutrophils for the elimination of
infections is evident from the fact that the absence of ROS production is associated with
high morbidity from severe infection (180). Azurophilic granules also contain a LPS
binding bactericidal permeability increasing protein (BPI) that provides potent
bactericidal activity against Gram-negative bacteria (181).
Initially thought to form part of the innate arm of immunity, it is now understood
that neutrophils play an important role in shaping the adaptive immune response against
invading microorganisms. Being the first cells to arrive at the site of infection,
neutrophils modulate different aspect of the immune response for effective clearance of
infection. There is evidence that other than mounting their own robust effector
mechanisms against infectious agents, neutrophils play a role in recruitment, activation
and programming of APCs (182). Apart from secreting chemoattractant chemokines,
neutrophils also recruit APCs with protease specific mechanisms that are unique only to
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neutrophils (183). Cathepsin G, a protease present in neutrophil granules mediates
proteolytic activation of prochemerin to chemerin, a substance that specifically attracts
APCs by engaging its ChemR23 receptor (184). Neutrophils also influence
differentiation of dendritic cells to activated macrophages by secreting chemokines. The
ability of dendritic cells to secrete IL-12 and TNF-alpha was severely curtailed in
neutrophil depleted mice infected with Toxoplasma gondi (182). Other than secretion of
cytokines, IL-12 and TNF-alpha by activated neutrophils, direct engagement of DCspecific, C type lectin, DC-SIGN with Mac-1 integrin of activated neutrophils induce
maturation of DC which in turn is important for inducing T cell activation and
proliferation (185). In addition, neutrophils can directly promote the proliferation and
maturation of B and T cells by secreting TNF-related ligand B-lymphocyte stimulator
(BLyS) (186) and interferon-gamma (187).
Neutrophils as Antigen Presenting Cells
In addition to creating an environment favorable for activation of B and
T lymphocytes, neutrophils also function as APCs in certain conditions. Treatment of
neutrophil cultures with GM-CSF, INF-gamma and IL-3 induces the expression of MHC
class II molecules (188, 189). Neutrophils cultured with GM-CSF showed de novo
synthesis of MHC class II molecules, along with CD80 and CD86. When incubated with
staphylococcus enterotoxin and tetanus toxoid along with T cells, these neutrophils
induced production of IL-2 and proliferation of T cells in a MHC class II restricted
manner (190). In vivo expression of MHC class II and costimulatory molecules (CD80
and CD86) were found on neutrophils from patients with Wegener’s granulomatosis
(191, 192) and also from neutrophils recovered from the inflamed joints of RA patients
(193). Neutrophils from normal healthy donors did not show constitutive expression of
MHC class II or co stimulatory molecules, but their expression could be induced when
neutrophils were cultured with T cells or T cell derived cytokines or with GM-CSF (192).
These examples provide evidence that neutrophils and T cells can cooperate to manifest
an adaptive immune response against microbial and perhaps against self antigens too.
Neutrophil Extracellular Traps: Unique Mechanism to Counter Infections
Fully differentiated neutrophils in circulation have two different fates - either to
undergo apoptosis in the absence of any stimuli or to migrate to the site of an active
infection and participate in microbial killing. Phagocytosis of microbes by activated
neutrophils is a known and well studied mechanism. Recently, it was observed that other
than phagocytosis, neutrophils kill microorganisms by releasing chromatin and granular
proteins to engage the microbes (194). These extracellar “traps” of chromatin are named
neutrophil extracellular traps (NETs) and contain proteins from both primary azurophilic
granules (myeloperoxidase, elastase and cathepsin G) and secondary granules
(lactorferrin and gelatinase) (194). DNA and histones form the meshwork of NETs and
bind to Gram-positive and Gram-negative bacteria (194) as well as fungi (195). NET
formation is now considered a unique form of programmed cell death, one that is
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different from both apoptosis and necrosis (196). Unlike in apoptosis, during the early
stages of NET formation, phosphatidylserine (PS) does not relocalize to the outside of
plasma membrane, DNA is not condensed or fragmented (at least initially) and caspases
are not activated. Necrosis differs from NET formation in keeping the nuclear and
cytoplasmic compartments separate with no appreciable changes in chromatin structure.
In contrast, NET formation progresses through distinct phases, where first
heterochromatin decondenses followed by a disintegration of nuclear membranes
allowing mixing of nuclear and cytoplasmic contents, and finally release of a chromatin
meshwork interlaced with cytoplasmic granular proteins from the cell (196).
The ability of neutrophils to deploy NETs is supported by the cytoskeleton in
neutrophils, as demonstrated by a reduction in NET formation following exposure to
agents that depolymerzise actin and microtubule filaments (197). Apart from
cytoskeleton elements, NET formation is also dependent on ROS production by
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (196, 198). Oxidative
burst is needed for NET release, as neutrophils from patients deficient in functional
NADPH oxidase subunits (who suffer from chronic granulomatous disease, CGD) are
unable to form NETs (196). Recently, it was discovered that Rac2, a GTPase known to
interact with NADPH oxidase is needed to make NETs (199). Also involved in NET
formation are two proteases, neutrophil elastase and myeloperoxidase (200, 201), that
degrade specific histones and allow chromatin release.
NET formation seems to be a late attempt by neutrophils to clear bacteria, as
treating neutrophils with DNase affects the ability of neutrophils to eliminate bacteria at
later time points (> 2 hours) (196). At earlier time points, DNase-treated and untreated
neutrophils are equally potent in clearing bacteria, suggesting that phagocytosis is the
primary mechanism employed by neutrophils. Apart from being morphologically unique
NET formation is also associated with a unique biochemical process -deimination of
histone arginine residues to citrulline (202). Exposure of neutrophils to inflammatory
stimuli induces activation of peptidylarginine deiminase IV (PAD4), the enzyme that
deiminates arginine residues on histones to citrullines (202). Activation of other PAD
isoforms in higher vertebrates is associated with physiological growth processes.
Deimination of histones during neutrophil activation in response to inflammatory stimuli
or infectious agents provides a unique example of self protein deimination in response to
external factors. The mechanism and regulation of NET formation is not fully
understood, but the hypercitrullination (deimination) of histones is presumed to play a
role in the decondensation of chromatin for extracellular release (203). It is likely that
the conversion of positively charged arginines to neutral citrullines reduces the
interactions between histones and negatively charged DNA. Does deimination of
histones facilitate NET formation? NET formation requires rapid decondensation of
chromatin (194). The linker histone H1 keeps the chromatin compact. Deimination of
core histones is known at present. Whether deimination occurs in linker histone H1, a
histone subtype responsible for maintaining the higher order structure of chromatin is still
to be determined (see Chapter 3).
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Deimination: a Post Translational Modification during Neutrophil Activation
During neutrophil activation, deimination of histones occurs as a result of the
action of PAD4. This enzyme belongs to a family of highly conserved, Ca++ dependent
enzymes known as peptidylarginine deiminases (PAD) (204, 205). Deimination of
proteins is notable because it transforms a positively charged amino acid (arginine) to a
neutral amino acid (citrulline) resulting in a net loss of one positive charge per
transformed residue. So deimination changes not only the primary sequence of a protein
is but also the net charge on the protein. During this reaction, the guanidino group of
arginine is attacked by the Cys residue of a PAD enzyme resulting in the formation of a
tetrahedral adducts. A nucleophilic attack by a water molecule then cleaves the adduct to
form a keto group of citrulline while releasing ammonia and regenerating the Cys residue
of the enzyme (206, 207). The net result is the conversion of arginine to citrulline with a
mass shift of +1 Da. PAD4 is the only member of this family that has a nuclear
localization signal and is therefore responsible for deimination of histone and other
nucleroproteins during neutrophil activation. Other members of the PAD family,
PAD1-3 and PAD6 have other tissue localization and substrate specificities.
Physiological Effects of Protein Deimination
Deimination of proteins changes their primary, secondary or tertiary structure and
also influences protein-protein interactions. Deimination may result in a loss of ordered
structure and denaturation of proteins (208). Deimination by causing loss of basic
residues and alterations in charge distribution results in loss of ionic interactions and
breaking of hydrogen bonds. In general, deimination results in a less compact
configuration of proteins. In epidermis keratin (K1 and K10), filaggrin and trichohalin
are known to undergo deimination (209, 210). After undergoing deimination,
profilaggrin acquires an open configuration that is more accessible to the neutral protease
calpain. Cleaved filaggrin units are osmotically active, contributing to hydration of the
skin (211). Deimination further causes small filaggrin units to bind keratin more
efficiently by lowering their isoelectric point and thus providing strength to the epidermis
(211). During early postnatal life, deiminated myelin basic protein binds less tightly to
gangliosides and thus provides the plasticity needed for brain development (212).
Without deimination development of nerve and hydration of skin suffers. Also, without
deiminating histones, neutrophils do not make NETs efficiently resulting in defective
bacterial clearance (203, 213). These examples illustrate the important role deimination
plays in the development of nerves, maintenance of skin characteristics and neutrophil
function.
Deiminated Proteins and Autoimmunity
Interest in deimination as a PTM that enhances and promotes autoimmunity
started when it was discovered that previously known anti-keratin antibodies associated
with rheumatoid arthritis actually recognize deiminated filaggrin (214). Later,
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autoantibodies against several other deiminated proteins were identified in RA patients.
These were directed against deiminated fibrin, vimentin and collagen. Many of these
deiminated proteins were identified in the synovial joints of RA patients (215, 216).
Detection of anti- deiminated protein antibodies paved the way for the development of
kits used for diagnosing RA with very high sensitivity and specificity (217-219).
Antibodies to deiminated proteins can be identified in the sera of RA patients even before
the onset of disease and have been associated with severe erosive arthritis (220, 221). All
these findings suggest that deimination plays an important role in the etiology of RA.
In addition to RA, deimination seems important for the etiology of multiple
sclerosis (MS). A higher percent of deiminated MBP is found in the nerves of children
that decreases with age (212). Deimination of myelin basic protein (MBP) found in adult
MS patients is comparable to early post natal levels (212). T cells that interact with
deiminated MBP were recognized in MS patients (222) as well as in mouse models of
MS (223). When tested, deiminated peptides of MBP induced more severe disease in
EAE models of MS than unmodified peptides (223).
How can peptides with one modified residue make such an impact in inducing
autoimmune disorders? Perhaps deimination of arginine results in generation of “neoepitopes” influencing antigen processing, presentation or recognition. Studies have
shown that positively charged P4 pockets of certain MHC class II molecules (of HLA DR
β-chain) can interact with citrullines better than arginine for antigen presentation (224).
Individuals which share a common epitope (EQKRAA) in the third hypervariable region
of the DRB chain of MHC molecules share increased susceptibility to RA (225, 226).
The genetic risk for RA is not limited to MHC haplotypes bearing the shared epitope but
extends to include additional MHC alleles and genes outside MHC region (227). A
genetic study of Japanese patient population found that certain haplotypes of PAD4
associate with an increased susceptibility for RA (228). The study revealed that the
mRNA of RA susceptible PAD4 haplotypes is 4-5 time more stable than the mRNA of
non-susceptible haplotypes (228). Increased mRNA stability of PAD4 may result in
more extensive deimination of proteins due to higher expression of PAD4. Other
evidence which points to the role of PAD4 induced deimination in RA includes the
presence of anti-PAD4 antibodies in anti CCP positive RA patients (229) and
colocalization of PAD4 and deiminated proteins in RA synovial tissue (230, 231). Also
patients with anti-PAD4 autoantibodies have a severe RA phenotype (232). Certainly
autoantibodies against deiminated proteins play a role in destruction of synovial tissues
and joints, but how these autoantibodies arise is not yet known.
Neutrophil Activation: Confluence of Factors for Initiation of Autoimmunity
against Deiminated Histones?
The following factors are implicated in predisposing to autoimmunity: 1. Genetic
background influencing immune signaling, antigen processing and presentation; 2.
Excessive cell death; 3. Defects in clearance of dead cells; 4. environmental agents
particularly infections and chemical pollutants; 5. Exposure of membrane bound antigens
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and 6; Post translational modifications generating ‘neo-epitopes’. Autoimmunity is a
multifactorial event and neutrophil activation can bring majority of above mentioned
factors together resulting in autoimmunity in susceptible individuals. In addition to
phagocytic response to clear infections, neutrophils employ NETs with extruded
chromatin laced with deiminated histones to contain infectious agents. Death of
neutrophils during NET formation adds to increased cell death seen during infection and
may overwhelm local clearance mechanisms. NETs also cause contact activation of
plasma kallikrein (PK) of intrinsic coagulation pathway (233). On one hand this results
in coagulation of clotting factors thereby augmenting microbial trapping while on the
other hand it results in the release of bradykinin, a potent proinflammatory peptide (234).
This along with the inflammatory cytokines released by neutrophils, resident
macrophages and epithelial cells generates a highly proinflammatory microenvironment.
Thus, neutrophil activation and NET formation increase the local concentration of
chemotactic and stimulatory cytokines that further enhance the infiltration of B and T
lymphocytes at the site of infection. Adjuvant effects of bacterial products such as LPS
can only increase the risk of initiating an unwanted immune response against NET
associated proteins.
Autoantibody targets on neutrophils were identified in SLE, small vessel
vasculitides and many of these targeted antigens are integral components of NETs (235238). Autoantibodies have been identified against neutrophil proteases- neutrophil
elastase, cathepsin G and proteinase 3 (PR3) (235, 236) as well as other bactericidal
substances, such as defensins and the LL-37 peptide (239, 240). In SLE patients
neutrophils are reported to have increased propensity to make NETs (241). These
patients also have increased serum levels of NETs and associated granular proteins (242)
as well as autoantibodies against them (243). Both levels of NET associated granular
proteins and autoantibodies against them correlate well with the severity of disease.
Released NETcomponents in SLE patients causes direct endothelial damage as well as
contributes to the production of type 1 IFNs from plasmacytoid dentritic cells (240, 242).
The fact that anti-DNA autoantibodies of lupus patients protect NETs from being
degraded by nucleases only adds to the persistence of NETs further amplifying the
damage (243).
Two major components of NETs are DNA and core histones that constitute about
70% of NET associated proteins (244). Histones are also well known autoantigens in
diseases like lupus (245) and Felty’s Syndrome (246). Of the 4 core histones present in
NETs, 3 (H2A, H3 and H4) are known substrates of PAD4. The fact that autoantibodies
are found against all major NET components and that histones in NETs undergo
deimination, a PTM that changes recognition of self antigens in a manner to initiate an
autoimmune response, made us think that autoantibodies against deiminated histones
should also arise in susceptible individuals. Therefore, we began this study to find
neutrophil involvement in autoimmune diseases.
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Aims and Objectives
Infections have long been suspected to play a role in the etiology of autoimmune
disorders. Though the role of infections in the initiation of autoimmune disease is not
clear, evidence of flares in autoimmune disease during episodes of infection support their
involvement in autoimmunity. Infections provide a unique confluence of events which
may promote initiation of an autoimmune response. First, infection can cause massive
recruitment and activation of neutrophils. Second, deimination a PTM known to alter
self antigens to “neo-epitope” is associated with neutrophil activation. Third, NET
formation brings deiminated histones to the outside from the confines of cellular
membranes and exposes them directly to the antigen presenting cells. Fourth, the
adjuvant effect of the trapped microbial components increases the efficiency of antigen
processing and presentation. Fifth, a variety of cytokines and chemokines released from
the activated neutrophils, macrophages and APCs at the site of infection recruits T and B
cells, some of which may be capable of binding to deiminated histones if central
tolerance against deiminated histone “neo-epitopes” is not established previously. Sixth,
the lack of any known mechanism for reversing deimination combined with the fact that
deiminated histones are embedded into exposed NETs encapsulating pathogen increases
the possibility that deiminated proteins persist in an environment suitable for recognition
by lymphocytes. Keeping these points in mind we formed our hypothesis that PTM,
particularly those that are introduced in a pro-inflammatory context (deimination),
are responsible for breaking tolerance.
In this study our main objective was to determine if deiminated histones are
targets in autoimmune diseases. In the chapters to follow we provide evidence for
autoimmune response against deiminated histones in patients with Felty’s syndrome (FS)
but not in SLE, RA and small vessel vasculitides (Chapter 1). Next, we identify linker
histone H1 as a new substrate of PAD4, provide evidence for deiminated H1 being an
autoantigen in SLE and map citrullines on H1 subtypes expressed in neutrophils (Chapter
2). Finally, we describe profound B cell tolerance to deiminated histone seen in both
non-autoimmune and autoimmune prone mice (Chapter 3).
Significance
Mechanisms involved in the breaking of tolerance to self antigens and initiation of
autoimmune disorders are multifactorial. Environment and infections seem to influence
the development and progression of autoimmune disorders. Autoimmune disorders flair
during infection indicating direct role for infectious agents in the disease progression.
Mechanisms like molecular mimicry of host antigens by microbial proteins have been
identified as directly contributing to autoimmunity. Though a direct contribution by
infections to autoimmunity has been established in some cases, in this study we looked
for evidence for indirect contribution of infections in breaking tolerance. We focused on
how an immune response (neutrophil activation) initiated to fight infections may
contribute to the initiation of autoimmune response. We found evidence for the presence
of autoantibodies against deiminated histones in a subset of patients with FS, SLE and
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RA. In contrast, autoantibodies from patients with vasculities preferentially bound to
non-deiminated histones over deiminated histones suggesting that different circumstances
or genetic differences can skew the autoimmune response to one form of histones.
Preferrential binding of anti-deiminated histone autoantibody containing sera to activated
neutrophils and the specific recognition of deiminated histones in activated neutrophil
lysates suggest involvement of neutrophils as source of deiminated histones to drive
autoimmune reaction.
In order to test the contribution of deimination in initiating an immune response
against self-antigens, we immunized BALB/c mice with deiminated histones. Our results
show that though deiminated histones are able to induce proliferation of deiminated
histone specific T cells, B cell tolerance to deiminated histones is similar to that against
non-deiminated histones. In mice with defective tolerance against histones (NZB X
NZW, NZM2410 and SLE congenic mice derived from them), we found that
spontaneously arising autoantibodies preferred non-deiminated histones over deiminated
histones. This suggests that B cell tolerance to deiminated histones is actively maintained
even in autoimmune prone mice. On futher investigation we found the presence of
deiminated histones in the spleen of autoimmune mice and conclude that deiminated
histones, probably from activated neutrophils, are trapped in the reticulo-endothelial
system of spleen (247) and help in maintaining peripheral tolerance against deiminated
histones even when tolerance to non-deiminated histones is compromised.
Alternatively, the preference of B cell response for non-deiminated histones over
deiminated histones may be due to differences in processing and presentation of the two
antigens. Proteolytic processing of proteins is a prerequisite for MHC loading. Though
many proteases of the lysosomal compartment have overlapping activity, certain
proteases are specific for digesting and presenting specific proteins. For example, tetanus
toxin C fragment (TTCF) is specifically cleaved by asparaginyl endopeptidase (248).
Consequently, APCs treated with inhibitors of asparaginyl endopeptidase, and not other
protease inhibitors, have reduced presentation of TTCF antigen (248). With regard to
deiminated histones, cleavage by neutrophil proteases may shift position relative to nondeiminated histones. Neutrophils express cathepsin H (249), a lysosomal cysteine
proteinase involed in antigen presentation (250). Cathepsin H recognizes arginine as its
major cleavage site. Neutrophils also express trypsin, a protease that cleaves proteins at
carboxy terminal of arginine. Thus, by deiminating arginine to citrulline, the loss of a
cleavage site on histones may result in different peptide fragments. Because histones are
abundant self proteins, it is not surprising that they are presented in MHC. Thus, an
arginine containing peptide from histone H2A (RIIPRHLQL) has been identified as a
natural endogenous ligand for HLA-G (MHC-1) (251). Deimination may change
presentation of this or similar histone peptides by MHC. Differences in presentation may
influence T cell central tolerance and B or T cell activation in the periphery. As
splenocytes from (NZB X NZW) F1 mice proliferated in response to both deiminated and
non-deiminated histones, we suggest that MHC presentation of deiminated histones is
intact in lupus prone autoimmune mice. Therefore, the preference of IgG binding for
non-deiminated histones may be due to the presence of a B cell tolerance mechanism to
deiminated histones.
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Our finding that autoantibodies to deiminated histones are present in humans with
FS represents the first instance where a product of the innate immune system is directly
targeted by an autoimmune response. Lack of autoantibodies against deiminated histones
in patients with vasculitis indicate that different genetic predisposition or environmental
circumstances determines whether an autoimmune response against deiminated histone
will be initiated or not. Our observation in autoimmune mice that peripheral tolerance to
deiminated histones is intact and separate from tolerance against non-deiminated histones
also points to the fact that different factors, both genetic and environmental, will
determine whether an autoimmune response will be initiated against either self-antigens.
Understanding tolerance against deiminated histones in autoimmune lupus prone mice
may increase the possibility of tolerance being manipulated in ways so as to to put an
autoimmune disease into long term remission.
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CHAPTER 2. FELTY’S SYNDROME AUTOANTIBODIES BIND TO
DEIMINATED HISTONES AND NEUTROPHIL EXTRACELLULAR
TRAPS*
Summary
To test the hypothesis that autoantigen modifications by peptidylarginine
deiminase IV (PAD4) increase immunoreactivity, sera from patients with systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA), Felty’s syndrome (FS), and ANCAassociated vasculitides (AAV), along with non-autoimmune controls, were tested for
binding to activated neutrophils, deiminated histones, and neutrophil extracellular traps
(NETs). IgG binding to LPS-activated neutrophils was assessed by confocal microscopy,
and binding to in vitro deiminated histones was measured by ELISA and Western blot.
In addition, we quantitated histone deimination in freshly isolated neutrophils from the
blood of patients. Increased IgG reactivity with activated neutrophils, particularly NETs,
was paralleled by preferential ELISA binding to deiminated histones over nondeiminated histones in a majority of FS but only rare SLE and RA sera. Immunoblotting
revealed autoantibody preference for deiminated histones H3, H4 and H2A in most FS
and a subset of SLE and RA patients. In patients with AAV, serum IgG preferentially
bound non-deiminated histones over deiminated histones. Increased levels of deiminated
histones were detected in neutrophils of RA patients. Circulating autoantibodies in
Felty’s are preferentially directed against PAD4-deiminated histones and bind to
activated neutrophils and NETs. Thus, increased reactivity to modified autoantigens in
FS implies a direct contribution of neutrophil activation and the production of
NET-associated nuclear autoantigens in the initiation or progression of FS.
Introduction
Autoimmune disorders such as systemic lupus erythematosus (SLE) or
rheumatoid arthritis (RA) may progress slowly and follow a chronic path with gradual
worsening of disease manifestations (252, 253). In other individuals, sudden flares of
more intense disease manifestations may interrupt lengthy periods of symptom
quiescence. One notable example of worsening in a chronically progressing disorder is
provided by Felty’s syndrome (FS), a variant of RA that is defined by arthritis involving
axial joints, enlargement of the spleen, and a decline in neutrophil numbers (254). The
decrease in neutrophil numbers is thought to be due to excessive activation of mature
neutrophils and their clearance in the patient’s spleen. Felty’s usually arises in 1-3% of
RA patients after 10 to 15 years of fairly typical symptoms (254).

* Adapted with permission. Dwivedi, N., J. Upadhyay, I. Neeli, S. Khan, D. Pattanaik, L.
Myers, et al. 2011. Felty's syndrome autoantibodies bind to deiminated histones and
neutrophil extracellular traps. Arthritis Rheum (In Press).
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In an alternative view, FS does not arise as chronic progression of RA. Instead,
Felty’s may be closely related to a T-cell form of large granular lymphocyte leukemia
(LGL) with which it shares its defining clinical features and an oligoclonal CD8+ T cell
expansion (255). Due to the neutropenia, FS patients experience an elevated risk of
infections. The factors determining the course of disease in any given patient are largely
unknown. A prevalent finding is that autoimmune disorders may worsen in parallel with
various types of infections (256), although it is difficult to separate environmental effects
from underlying genetic and stochastic contributions.
Just how infections may affect autoimmune reactivity and potentially lead to
sudden flares in the presentation of autoimmune disorders is not established. One
possibility is that, as result of infection, the number of apoptotic cells could transiently
rise because diverse pathogens induce apoptosis in infected cells (257). The increased
numbers of apoptotic cells may exceed the clearance capacity of tissue-resident
scavenger cells and lead to the stimulation of the immune system with antigens from the
apoptotic cells (105, 258). This proposed mechanism is consistent with the increased risk
of autoimmunity arising from genetic defects in serum factors that recognize and bind
apoptotic cells or defects in phagocyte receptors that function in uptake and clearance of
apoptotic cells (258). Whether inefficient clearance of cells that die from other forms of
cell death also increases the risk of autoimmunity has been less thoroughly tested.
An alternative form of cell death that is induced during an infection is “NETosis”.
NETosis received its name from neutrophil extracellular chromatin traps (NETs) that are
released in response to infectious agents ranging from bacteria to fungi (194). Once at
the site of an infection, neutrophils deploy extracellular chromatin that is studded with
additional bactericidal granule components and may serve to immobilize and destroy
microbes (244, 259). The release of NETs is induced by a wide range of inflammatory
stimuli (202) and depends on signals from the cell surface and the participation of the
cytoskeleton (197). Autoantibodies to NET components, including lactoferrin, lysozyme
and elastase (260, 261), arise in autoimmune disorders, suggesting that NETs should be
viewed as possible stimuli for such antibodies. Nevertheless, conclusive evidence linking
NETs to the induction of autoantibodies is lacking.
Core histones in NETs contain arginines that are converted to citrullines (202) by
peptidylarginine deiminase 4 (PAD4), a post-translational modification (PTM) that is
essential for NET release (213). PAD4 acts on various autoantigens (210, 262-266), such
that antibody reactivity against citrulline-containing peptides has proven useful in the
diagnosis of autoimmunity. In RA, autoantibodies react with a peptide of filaggrin,
provided it contains citrulline (267), and anti-cyclic-citrullinated-peptide (anti-CCP)
autoreactivity constitutes a reliable marker for this condition (217).
Because histones are the major substrates of PAD4 (268), and because antihistone antibodies are produced in SLE (245), RA (269) and FS (246), we hypothesized
that, if NETs are the source of the autoantigens, autoantibodies from patients with these
disorders might bind deiminated histones with preference over non-deiminated histones.
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Our results with FS sera support this hypothesis: By immunofluorescence, ELISA, and
Western blotting, we found preferential binding to deiminated histones H3, H4, H2A or
H1. In comparison, only few RA and SLE sera showed preferential binding to
deiminated histones. A control group of patients with anti-neutrophil cytoplasmic
autoantibody (ANCA)-associated vasculitides (AAV) expressed antibodies with
preference for non-deiminated histones over deiminated histones. We propose that
activated neutrophils contribute as sources of deiminated autoantigens to the pathogenesis
of FS.
Patients and Methods
Patient Sera
Sera were collected at the University of Lubeck, the Hospital for Special Surgery,
from UTHSC, and from the Veterans’ Administration RA (VARA) serum repository
(270) and used in accord with IRB approvals from each of the participating institutions.
All patients fulfilled the American College of Rheumatology classification criteria for
RA (271) or SLE (272) or ANCA vasculitis (273). Felty’s syndrome was clinically
defined by the coexistence of RA, chronic neutropenia (<2000/l), and splenomegaly
(254), except that VARA participants were classified as having FS based on the
determination of an International Statistical Classification of Disease (ICD-9) code
corresponding to this disorder (714.1).
Neutrophil Isolation and Stimulation
Neutrophils were isolated from healthy donor blood (Key Biologics, Memphis,
TN), or from patients with RA or FS, as described (202). Briefly, neutrophils were
enriched using dextran sedimentation, recovered by isolymph density gradient (GallardSchlesinger, Plainview, N.Y, USA), and suspended in PBS (without Ca++/Mg++) with
0.1% glucose and 0.5% heat-inactivated human serum. Neutrophils were stimulated with
100 ng of LPS/ml of HBSS or PBS, 2mM Ca++, for 2 hours, and lysed in 2% SDS, 5%
2-mercaptoethanol and 10% glycerol in 62.5mM Tris, pH 6.8. Alternatively,
autoimmune or control sera were diluted to 2 g/ml of IgG and used in place of LPS.
Confocal Microscopy
Purified neutrophils were allowed to settle onto poly-L-lysine-coated glass
coverslips and examined as described (202). Cells were treated with LPS (100 ng/ml) for
1 hour at 37°C, rinsed with ice-cold HBSS, and fixed with 4 % paraformaldehyde in
HBSS. Coverslips were incubated with patient serum (10 g/ml IgG) or rabbit anticitrullinated histone H3 Abs (Abcam, Cambridge, MA, Cat # ab5103) at 1:100 dilution
for 1 hour. Antibody binding was detected with goat anti-human IgG-AF647 or goat
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anti-rabbit IgG-AF488 and Sytox orange (all from Invitrogen) and analyzed by confocal
microscopy.
ELISA
Calf thymus histones or recombinant human histone H3.3 (Millipore Corp.,
Billerica, MA), were incubated with 0.2 µM recombinant PAD4 to completion of
reaction as described (274). Flat bottom, 96 well microtiter plates (Immulon 4HBX)
were coated with 5 µg/mL of deiminated or non-deiminated histones. As control,
recombinant PAD4 was added to histones in the presence of EDTA to test whether
binding to PAD4 confounded our ELISA readings. Blank values were determined from
plates incubated with coating buffer. Plates were blocked with 2.5% BSA in PBS, and
sera were serially diluted from 20 g/ml of IgG and incubated for 2 hour. Binding was
quantified using goat anti-human IgG alkaline phosphatase (Southern Biotech,
Birmingham, AL) after addition of phosphatase substrate (Sigma) and measurement of
optical density. ANCA were detected by immunofluorescence or capture ELISA, as
described (275). Anti-citrullinated protein antibodies (ACPA) were measured by anticitrullinated vimentin or anti-CCP ELISA, according to manufacturers’ instructions.
Western Blot
Proteins were resolved by 15% SDS-PAGE and transferred to nitrocellulose.
Membranes were blocked in 5% BSA, 0.1% Tween 20 in TBS and incubated with patient
sera at 5 µg/ml of IgG in TBS containing 2.5% BSA, 1% NP-40 and 0.1% SDS for 2
hours. Anti-human IgG–HRP was used for chemiluminescence development with
“Western Lightning” substrate (PerkinElmer).
Statistical Analysis
We used an unpaired, two-tailed t test to evaluate whether FS IgG had greater
preference for deiminated histones than IgG from other experimental groups.
Chemiluminescence images of Western blots were scanned and the differences in binding
between different sera were evaluated by paired permutation test, as described in the
results. The relative abundance of deiminated histones in neutrophils ex vivo was
determined by dividing the intensity of binding to deiminated histone H3 by the total H3
binding intensity. The statistical differences between the groups were computed by
Mann-Whitney (Wilcoxon) Rank test.
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Results
Characteristics of Patient Populations
To analyze potential mechanisms that induce autoreactivity, we collected sera
from 32 patients with SLE, 37 with RA, 23 with FS, 55 with small vessel vasculitides,
along with 10 healthy controls. Patient data are given in Table 2-1. Despite the fact that
SLE, RA and FS primarily affect women, patients included 67 females and 76 males who
ranged from 13 to 88 years of age (avg. 62). The male predominance is because 34 of the
FS and RA samples were from the VARA repository which contains mostly male
patients. Disease was active in 52 of 60 RA and FS patients, whereas 22 of the SLE
patients had inactive disease. In addition, our study also included 32 males and 23
females with active vasculitis, including 25 patients with WG, 15 with MPA and 15 with
CSS. Most patients were treated with combinations of azathiopine, prednisolone,
methotrexate and endoxan, and 10 RA or FS patients were on anti-TNF therapy (Table
2-1). Clinical assays were performed to assess the levels of anti-citrullinated protein
antibodies (ACPA or anti-CCP). Most (17 of 23) FS patients and (22 of 37) RA patients
had antibodies to citrullinated antigens, an indication of more rapidly progressing
arthritis. In contrast, 24 WG patients and 14 MPA patients contained ANCA that
predominantly bound PR3 or MPO respectively (Table 2-1). The clinical usefulness of
these assays was recently evaluated (275, 276).
Neutrophil Activation Increases Autoantibody Reactivity
Neutrophils respond to bacterial breakdown products, such as LPS, and other proinflammatory stimuli by releasing granule enzymes and casting chromatin NETs (244,
259). These complex morphological and enzymatic reactions could potentially affect
autoantibody binding. To test whether neutrophil activation increases autoantibody
reactivity, we prepared neutrophils from healthy donors, exposed them to LPS or left
them untreated, and measured binding of IgG from SLE, RA, and FS patients. Bound
IgG was detected with fluorescent rabbit anti-human IgG antibodies and visualized
relative to DNA (Figure 2-1). Control serum IgG did not detectably bind to unstimulated
neutrophils or to activated neutrophils (Figure 2-1B). In contrast, IgG from FS, SLE and
RA patients reacted strongly to LPS-activated neutrophils (Figure 2-1D, F, H, J, L and
N), yet binding to unstimulated neutrophils remained low.
Binding of patient IgG to NETs was particularly striking. FS2 IgG binding
largely overlapped with NET chromatin (Figure 2-1D), and IgG binding closely matched
the lace-like distribution of dispersed nuclear DNA. A similar pattern of IgG binding
was observed with the FS3 serum (Figure 2-1F). The binding of RA3 and RA4 IgG was
focused into domains that mostly coincided with the location of DNA, although certain
patches of chromatin remained unbound (Figure 2-1H and J). Binding of SLE6 IgG was
observed in close association with NETs and it extensively overlapped with the
extracellular chromatin (Figure 2-1L), as did SLE7 IgG, whose binding closely matched
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Table 2-1:

Characteristics of patients

Parameters
SLE RA
FS
WG MPA CSS Non-AI
Patients (n)
32
37
23
25
15
15
10
Male (n)
3
18
17
16
7
9
8
Female (n)
29
19
6
9
8
6
2
Mean Age (yrs)
35.2 64.9
70.3
54.7
67.4 60.7
36.2
Active Disease
10
31
21
25*
15
15
pANCA(α-MPO) +ve
1
1
2
14
cANCA (α-PR3) +ve
1
1
23
ACPA +ve
2
22
17
1
Azathiopine
9
2
3
1
Prednisolone
26
24
8
24
12
14
Methotrexate
1
25
12
9
3
2
Endoxan
2
9
5
8
Hydroxychloroquine
17
Mycophenlate
9
Anti-TNF
4
6
* Sera from the WG patients were also tested in the inactive phase of disease.
(Abbreviations: SLE, Systemic Lupus Erythematosus; RA, Rheumatoid Arthritis; FS,
Felty’s Syndrome; WG, Wegener’s Granulomatosis; MPA, Microscopic Polyangiitis;
CSS, Churg-Strauss Syndrome; Non-AI, Non-Autoimmune.)
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Figure 2-1: Binding of autoimmune sera to activated neutrophils
Autoimmune or control IgG bound to unstimulated or LPS-stimulated neutrophils (A-N).
Representative sera shown are: Control serum (CS; panels A and B), FS2 (C and D), FS3
(E and F), RA3 (G and H), RA4 (I and J), SLE6 (K and L), SLE7 (M and N). Stimulated
neutrophils, having released NETs, react more strongly with autoimmune IgG.
Anti-human IgG alone did not bind (O). Stimulated neutrophils reacted with antideiminated histone H3 (green fluorescence in P). Anti-IgG binding is displayed in red
and DNA in blue.

31

32

the distribution of NET DNA (Figure 2-1H). The pattern of patient IgG binding
resembled, in most instances, the distribution of deiminated histone H3 (Figure 2-1P).
The congruent distributions of IgG immunoreactivity and of deiminated H3 suggested
that, at least in part, immunoreactivity may be enhanced by histone deimination.
Preferential Antibody Binding to Deiminated Histones in ELISA
Previous reports had indicated that neutrophils efficiently deiminate core histones
(268). Our own data confirmed that core histones are the major substrates of PAD4
deimination in activated neutrophils (Figure 2-2), although a number of other proteins
also are PAD4 substrates. To directly assess whether deiminated histones are preferred
targets for FS, RA, or SLE patient autoantibodies, we deiminated histones in vitro and
measured IgG binding by ELISA.
Binding curves were determined for 23 FS, 37 RA and 32 SLE sera. Figure
2-3A-D shows representative curves. Five of six FS sera showed IgG binding to histones
in ELISA, and, for each of those 5 sera, binding to deiminated histones exceeded binding
to non-deiminated histones by 2 to 10-fold (Figure 2-3A). The sixth sample showed
negligible binding. In contrast, RA sera bound less avidly to histones and, except for
one, the sera showed little to no preference for deiminated histones (Figure 2-3B).
Histone binding was most pronounced with SLE sera, yet except for one serum (triangles
in Figure 2-3C), the binding to deiminated and non-deiminated histones was comparable.
In the exceptional serum, IgG binding to deiminated histones was more than 30-fold
stronger than to non-deiminated histones. Control (Non-AI) sera showed very little to no
binding to either type of histone (Figure 2-3D). LG2-2, a mouse monoclonal anti-H2B
(277), gave equivalent binding to either substrate, thus indicating equal coating of plates
with deiminated and non-deiminated histones (Figure 2-3E).
We subtracted the binding to non-deiminated histones from the binding to
deiminated histones at 6.6 g/ml IgG (in the linear range of titration curves), in order to
determine the relative binding preference for deiminated histones (Figure 2-3F). This
measure indicated that FS sera were unique among the sera tested, in that binding to
deiminated histones was generally higher than binding to non-deiminated histones. The
SLE group had one serum with greatly enhanced preference for deiminated histones, and
other sera that bound with only low relative preference to deiminated histones. IgG from
RA sera showed only slightly higher binding to histones than control sera and only two
sera bound preferentially to deiminated histones in ELISA. These data indicate that FS
patients differ significantly from RA and SLE patients in their preferential antibody
binding to deiminated histones.
Autoantibodies Distinguish between Different Deiminated Histones
The ELISA with total histones revealed binding preferences that were robust and
directed at native antigens. However, the ELISA may not have detected subtle
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Figure 2-2: Neutrophil substrates of PAD4
Neutrophil extracts were probed for citrulline by Western blot. Lanes 1 and 2:
Neutrophils treated with or without calcium ionophore. Lanes 3, 4 and 5: Freeze thaw
lysates of neutrophils maintained in the absence of Ca++ (Lane 3), in the presence of
2mM Ca++ (Lane 4), or in the presence of 2mM Ca++ with added Cl-amidine, a PAD4
inhibitor. Arrows indicate putative core histone bands that exceed multiple other
deiminated proteins in staining intensity.
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Figure 2-3: Serum IgG binding to deiminated or non-deiminated histones
Sera from FS (A), RA (B), or SLE patients (C) and controls (D) were tested for binding
to deiminated (red) and non-deiminated histones (blue) and OD values were plotted.
Mouse anti-histone H2B (LG2-2) was used as standard (E). Differences in binding were
computed for each serum (F). Different symbols represent different sera. Brackets in
panels B and C identify sera with the greatest preference for deiminated histones.
Asterisks indicate statistical significance between groups (FS vs. RA: p = 0.017; FS vs.
SLE: p = 0.042; and FS vs. Non AI: p = 0.047).
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preferences directed at individual histones. To determine which histones are
preferentially bound by autoantibodies, we separated deiminated and non-deiminated
histones by SDS-PAGE and probed them with patient and control sera (Figure 2-4). As
shown by Coomassie Blue staining, both types of histones were present in equivalent
amounts. Moreover, the faster mobility of the deiminated histones and their
immunochemical reaction pattern indicated that, as expected, three core histone contained
citrullines.
The majority of FS sera and a minority of the RA and SLE sera (some, e.g. RA1,
quite weakly) bound with preference to one or more deiminated histones (Figure 2-4).
Most of the samples that scored positive for antibodies to deiminated histones bound
deiminated H3, although preferential reactivities to deiminated H2A (FS2) or H4 (SLE8)
were also observed. Preferential binding to citrulline-containing epitopes from different
core histones demonstrates that flanking sequences contribute to antibody binding.
Preferential binding to deiminated over non-deiminated histone H3 was
confirmed by probing multiple gels and quantifying the statistical significance of binding
(Table 2-2). In short, chemiluminescence images of Western blots were scanned and
analyzed using Photoshop imaging software. Western blots were repeated at least 4 times
for each patient serum. Different exposures were developed in order to establish the
saturation range of the x-ray film. Films were scanned under constant settings of
brightness/contrast in all cases. Band intensities were converted to numerical values
using the histogram function of Photoshop. These numerical values were used to
compare binding to the following pairs of histones: deiminated vs. non-deiminated H3,
and deiminated H3 vs. deiminated H4. P values were computed to ascertain differences
in Ab binding to different proteins by paired permutation (exact) test using R Software
(online at http://www.R-project.org). Since permutation tests are based on randomly
generated permutations, the p values for each data set were computed 100 times and the
means of all the p values were tabulated. Differences were taken as significant if the p
value was less than 0.01.
Interestingly, four sera (FS2, RA8, SLE5 and SLE6) preferentially bound to a
deiminated protein migrating near 35 kD. The anti-citrulline antibody (Anti-Cit) detected
a band migrating near 35 kD, the approximate size of linker histone H1, suggesting that
histone H1 is recognized by a variety of patient sera. Although it will be necessary to
conclusively demonstrate that H1 is a substrate for PAD4, the possibility is intriguing
because H1 controls the higher order structure of chromatin. The analysis of patient sera
by Western blot confirmed the striking preference of FS antibodies for deiminated
histones and identified histone epitopes that may be particularly autoreactive.
Autoantibodies from ANCA-associated Vasculitides Prefer Non-deiminated
Histones
As a control, we analyzed anti-histone autoantibodies in autoimmune disorders
characterized by anti-neutrophil immunoreactivity. Wegener’s granulomatosis (WG),
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A

B

Figure 2-4: Autoantibodies distinguish different histones
(A) Representative SLE, RA, and FS sera exhibit different preferences for individual
deiminated or non-deiminated histones. Deiminated (left lanes) or non-deiminated
histones (right lanes) were resolved on SDS-PAGE and stained (Coomassie) or reacted
with anti-citrulline (Anti-Cit) on blots. Binding of IgG from autoimmune patients (FS,
RA or SLE) to histones was detected by Western blot. (B) AAV sera preferentially
recognize non-deiminated histones. Western blots were performed with sera (2 MPA, 2
CSS and 3 WG) that bound histones. FS2 serum was used as positive control. Increased
binding to individual histones is marked by symbols. Filled symbols indicate preference
for deiminated histones, open symbols preference for non-deiminated histones. Circles
denote histone H3, squares H2A, up triangles H4, and down triangles histone H1.
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Table 2-2:

Statistical analysis of IgG binding to histones
p Value
Cit H3 and H3
Cit H3 and Cit H4
0.055015
0.14042

Disease
Control

Patient
CN

(n)
8

Felty

FS1
FS2
FS3
FS4
FS5
FS6

8
10
9
8
8
NA

0.00783
0.001745
0.003945
0.007955
0.00777
NA

0.00775
0.00189
0.003785
0.00749
0.007805
NA

RA

RA1
RA2
RA3
RA4
RA5
RA6
RA7
RA8
RA9
RA10

9
11
10
9
11
10
9
8
11
NA

0.003885
0.000865
0.45125
0.003635
0.40277
0.00185
0.78527
0.60146
0.022915
NA

0.00387
0.00094
0.51419
0.00374
0.002895
0.031205
0.38305
0.007595
0.000885
NA

SLE1
9
0.00419
0.0039
SLE2
8
0.09374
0.054245
SLE3
9
0.16782
0.00758
SLE4
NA
NA
NA
SLE5
8
0.007865
0.00782
SLE6
8
0.007935
0.00807
SLE7
9
0.015795
0.00378
SLE8
11
0.1299
0.004625
SLE9
8
0.03158
0.03125
SLE10
NA
NA
Paired permutation test was used to calculate p values for the identity in binding to
deiminated and unmodified histones. Comparisons were made between deiminated H3
and unmodified H3, and between deiminated H3 and deiminated H4. Values of less than
0.01 were considered significant (bold). The number of observations is indicated by (n).
SLE
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microscopic polyangitis (MPA) and Churg Strauss syndrome (CSS) constitute a group of
vasculitis disorders associated with ANCA (278). The characteristics of 25 patients with
WG, 15 patients with MPA and 15 patients with CSS vasculitis, including their
autoantibody profiles and therapy, are shown in Table 2-1. By ELISA, only 7 AAV
patient sera bound to histones (data not shown). When those sera were tested by Western
blot, all 7 AAV sera preferentially bound non-deiminated histones over deiminated
histones (Figure 2-4). As before, the FS2 serum preferentially bound deiminated
histones. These results showed that AAV patients overall have a low incidence of antihistone autoantibodies and that binding of those antibodies is inhibited by deimination.
LPS Stimulation of Neutrophils Generates Preferred Histone Autoepitopes
The preceding experiments demonstrated that in vitro deimination of histones
with PAD4 affects autoreactive IgG binding. To test whether neutrophil activation also
generates autoepitopes that mediate autoreactive IgG binding, we exposed neutrophils to
LPS for 2 hours and probed blots of neutrophil lysates with FS2 and a control antiserum
(Figure 2-5). Indeed, the FS2 antibodies showed preferential binding to a protein
migrating with the expected mobility of deiminated histone H3, providing evidence that
the relevant FS2 IgG histone autoepitopes are generated by neutrophil exposure to
inflammatory stimuli. In addition, other proteins were immunoreactive, and LPS
stimulation broadly increased the binding of FS2 IgG to cell extracts (Figure 2-5A).
These results were consistent with the induction of immunoreactive epitopes by PAD4
activation in neutrophils.
Deimination Is Responsible for Preferential Histone Binding
Histones accept numerous post-translational modifications (PTM) that, in various
combinations, constitute a “histone code” (279). In order to exclude possible
contributions of other PTM to the preferential binding of autoantibodies, we used histone
H3.3 produced in E. coli and thus devoid of eukaryotic PTM. We deiminated H3.3 with
PAD4 in vitro. In parallel, we deiminated BSA to test IgG cross-reactivity with
citrullines in an unrelated polypeptide.
By Western blotting, FS2 IgG bound with strong preference to the deiminated
histone H3.3 over the non-deiminated histone. This result indicated that citrulline is a
major determinant of FS2 IgG binding. Furthermore, a low level of binding to
deiminated BSA was also observed (Figure 2-5B), suggesting that binding can
accomodate some degree of heterogeneity in flanking sequences.
To localize FS2 IgG binding relative to deiminated histone H3, we stimulated
neutrophils with LPS on coverslips and incubated them with FS2 serum dilutions and
rabbit anti-deiminated histone H3. Binding was visualized with anti-human IgG and antirabbit IgG antibodies (red vs. green in Figure 2-5C). The FS and rabbit antibodies were
detected along NET chromatin that was visualized with Sytox orange. The extent of
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Figure 2-5: FS2 IgG prefer activated neutrophils, deiminated recombinant
histone H3.3, and NETs
(A) Equal amounts of proteins from unstimulated (U) or LPS-stimulated (S) neutrophils
were stained by Coomasie, or probed with FS2, or control sera. Protein of histone H3
mass (arrow) was more reactive with FS2 IgG following LPS treatment. Control serum
(CS) did not bind. (B) Non-deiminated (H) or deiminated (C) H3.3 and BSA were
probed on Western with FS2 IgG. LPS-stimulated neutrophils were reacted with FS2 (C)
or control sera (D). IgG binding is shown in red, DNA in blue and Anti-Cit H3 in green.
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colocalization between the antibodies and DNA was nearly complete, revealing clusters
of FS2 IgG along the extended NET chromatin fibers (bottom left of Figure 2-5C). This
confirmed that FS2 serum contains antibodies that recognize deiminated H3 and other,
more discontinuously arranged NET components. FS2 IgG also bound neutrophils prior
to the release of nuclear chromatin, suggesting that autoantigen PTM occur in
cytoplasmic foci of LPS-activated neutrophils.
Circulating Neutrophils from RA Patients Show Spontaneous Activation
To assess histone deimination in circulating neutrophils from RA, FS and control
subjects, we isolated neutrophils and probed them for deiminated histone H3 by Western
blot. Deiminated H3 signal intensities were normalized relative to total H3. The relative
intensities showed a 2.9-fold higher level of H3 deimination in RA neutrophils over
controls (Figure 2-6A; p<0.008). The increased levels of deiminated histones in
circulating neutrophils from RA patients suggest a greater degree of PAD4 activation. In
contrast, we observed no significant increase in histone deimination in FS over control
neutrophils (p>0.1).
To explore whether sera from FS, RA or SLE patients contain substances that
activate neutrophils, we incubated neutrophils from healthy donors with 2 g/ml of
patient sera and observed histone H3 deimination at 2 hours of incubation. Both SLE and
FS sera induced H3 deimination, suggesting the presence of immune complexes or
cytokines that activate neutrophils, whereas RA sera were inactive as inducers of PAD4
in neutrophils (Figure 2-6B). Control sera showed low or undetectable H3 deimination.
Discussion
Autoantibodies target diverse PTM in autoantigens (67, 280-282), yet few PTM
are uniquely associated with infections and inflammation. The exception is histone
deimination by PAD4. A variety of inflammatory stimuli induce histone deimination in
neutrophils, whereas apoptosis suppresses deimination (202). Here, we demonstrate that
autoantibodies to deiminated histones are prevalent in patients with FS. In contrast,
autoantibodies to deiminated histones are rare in RA and SLE, and absent from patients
with ANCA-associated vasculitides. Our results thus suggest that inflammatory
activation of neutrophils plays a central role in the induction of FS.
Our observations match findings of others that NET components are antigens in
autoimmunity. Autoantibodies from patients with systemic autoimmunity recognize
innate immune defense proteins that associate with NETs. This is the case for the granule
proteases elastase, cathepsin G and proteinase 3 (235, 236, 238) as well as for various
bactericidal peptides that are stored in granules and co-purify with NETs, such as
neutrophil defensins and the LL37 peptide (239, 240). PAD4, the enzyme responsible for
histone deimination, is an autoantigen in RA patients (283) and anti-PAD4 antibodies
precede development of clinical disease and predict its severity (284). In turn, a growing
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Figure 2-6: Deiminated histone H3 in circulating neutrophils and neutrophil
stimulation by autoimmune sera
Neutrophil lysates were prepared from freshly isolated neutrophils from RA, FS and
control subjects. H3 deimination was determined by rabbit anti-deiminated histone H3
and normalized for total H3. The normalized amounts of deiminated H3 were plotted
relative to the controls (set to 1). Horizontal lines represent the mean (thick line) and
standard deviation (thin lines) for the groups. The difference between the RA and control
groups was statistically significant (p value =0.008) but not the difference between the FS
and control groups (p >0.1). (B) Neutrophils were stimulated by autoimmune sera
diluted to 2 µg/ml of IgG and analyzed for histone H3 deimination (dH3). The blot was
stripped and reprobed with rabbit anti-total H3.
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number of PAD4 substrates have been recognized as targets of autoantibodies. These
include deiminated vimentin (264) and proteins of the extracellular matrix (210, 263,
266), suggesting that PAD4 is active both inside and outside of cells.
How PAD4 may act on extracellular substrates became clear when it was
discovered that PAD4 activation is part of the innate immune response to infections
(202). Neutrophils release nuclear chromatin and associated enzymes in response to an
encounter with pathogens (194, 244). The externalized chromatin entangles pathogens
and thus becomes linked to potent adjuvants that may stimulate adaptive immunity (285).
Clearly, uptake and presentation of “NET-ted” pathogens juxtaposes microbial antigens
and NET autoantigens, including DNA and histones. Upon pathogen uptake and
processing, self and foreign antigens may be presented to T cells. The identification of
autoantibodies to deiminated histones strongly suggests that NETs provide a source of
autoantigens in vivo. Identification of autoantibodies to deiminated histones and other
NET components (244, 260, 261) implicates NETs as the stimulus for autoantibody
production and suggests a link between infections or inflammation and the development
of autoreactivity.
To directly examine the availability of autoantigens in vivo, we quantified
deiminated histone H3 in freshly isolated blood neutrophils from RA, FS and control
subjects by Western blot. We observed nearly 3-fold higher levels of deiminated histones
in RA patients relative to controls (Figure 2-6A), suggesting ongoing spontaneous
activation of circulating neutrophils. In FS, deiminated histones were not significantly
elevated relative to controls. Because FS exhibits spontaneous activation and accelerated
clearance of circulating neutrophils, our observation may be skewed by the fact that an
elevated proportion of circulating neutrophils in FS is comprised of immature
(PAD4-negative) neutrophils (286). Thus, the deiminated histones that were detected in
FS neutrophils may have been derived from a small fraction of total neutrophils that
expressed sufficiently high levels of PAD4. The observation of a potent neutrophilstimulating activity in FS and SLE sera (Figure 2-6B) supports this conclusion.
Together, these results suggest the depletion of mature neutrophils from FS patients and
the chronic generation of neutrophil-derived autoantigens.
In certain forms of vasculitis, neutrophils are hyperactivated and serum levels of
neutrophil granule components are elevated in parallel with more advanced disease (287).
In addition, the severity of lupus correlates with the levels of autoantibodies to the NETs’
structural scaffold, DNA (243). Other studies directly point to neutrophil activation as a
key factor in the stimulation of autoantibodies. Notably, SLE patients’ neutrophils show
an exacerbated response to autoantibody complexes and are more prone to NET release
(241). One interesting aspect of these and our studies is that reactivities to different NET
antigens correlate with different disease manifestations. Just as PR3-ANCA
predominantly occur in WG and MPO-ANCA in MPA (288), the anti-deiminated histone
autoantibodies associate selectively with FS. We interpret the rare development of antideiminated histone antibodies in RA as indication that tolerance to histones remains
active and resilient even after development of clinical disease. Tolerance to deiminated
histones may only be broken after strong stimulation of adaptive immunity by unique
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epitopes that drive both B and T cell expansion.
In closing, we propose that anti-deiminated histone autoantibodies are markers
deserving particular attention in patients with severe inflammation and chronic activation
of neutrophils who may be at risk of progressing to more severe disease. Chronic
presentation of deiminated antigens may, over time, lead to the development of antigenspecific responses that target the modified antigen determinants and contribute to the
development of other clinical features of FS. The data presented in this study allow us to
propose a model of FS pathogenesis that is based on the biological properties of
neutrophils, the disease manifestations of FS, and our data on the high incidence of
autoantibodies to deiminated histones. In FS, pre-existing arthritis and an increased
incidence of infections may stimulate a neutrophil response that includes histone
deimination and the expulsion of chromatin from the cell. NETs containing deiminated
histones, in complex with bacterial adjuvants, are the most likely antigenic trigger to
account for the production of autoantibodies to the modified histones. These
autoantibodies or their immune complexes may further stimulate neutrophils, thus
completing a self-sustaining cycle that drives depletion of mature neutrophils.
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CHAPTER 3.

AUTOANTIBODY RECOGNITION OF CITRULLINE IN THE
GLOBULAR DOMAIN OF LINKER HISTONE H1
Summary

B cells producing anti-nuclear autoantibodies require a source of antigens.
Extracellular chromatin, released from activated neutrophils at sites of inflammation, may
provide access to nuclear autoantigens. Deimination, a posttranslational modification of
arginine to citrulline by PAD4, plays an important role in neutrophil chromatin release,
and deiminated histones thus represent a mark of inflammation. Here, we identified
autoantibodies in sera from systemic lupus erythematosus and Sjögren’s syndrome
patients that preferentially bound deiminated histone H1.2 over the unmodified H1.2.
One serum bound epitope included a citrulline located at a highly conserved position in
the H1.2 globular domain. We inventoried H1 histone subtypes in human neutrophils by
RNA expression and by mass spectrometry. We mapped citrullines by liquid
chromatography and tandem mass spectrometry. The data indicate that deimination of
linker histones generates H1 isoforms with enhanced autoimmune potential.
Introduction
Autoantibodies in systemic autoimmune disorders such as systemic lupus
erythematosus (SLE), Sjögren’s disease, or scleroderma often target nuclear antigens
such as DNA and histones(289-291). How such antigens engage B cells and induce
autoantibodies remained unclear until circumstances were uncovered in which chromatin
antigens become accessible at the cell surface (77, 292) . Immunochemical analysis of
apoptotic cells revealed that nuclear fragments bleb from the plasma membrane, thus
exposing DNA and core histones to the external milieu (293). When clearance of
apoptotic cells is inefficient, apoptotic blebs may supply nuclear antigens to B cells
(105). However, autoantibodies to the linker histone H1 represented an exception to this
pathway. Anti-H1 bound to early apoptotic cells but the binding to surface blebs was
undetectable (293). This observation raised the question whether different circumstances
are necessary for the exposure of H1 to the extracellular space.
In viable cells, the H1 linker histones bind DNA at the entry and exit points of the
nucleosome core particle, thereby determining the trajectory of linker DNA that connects
neighboring nucleosomes (294). By controlling the stacking of adjacent nucleosomes,
H1 modulates overall features of the chromatin fiber. In addition, H1 histones control
access to internucleosomal DNA, thus contributing to the regulation of gene expression
(295). The involvement of H1 in the control of higher-order chromatin structure and
gene transcription is reflected in the expression of multiple, structurally diverse and celltype-specific isoforms of H1(296).
The capacity of H1 histones for chromatin condensation is modulated by a
repertoire of post-translational modifications (PTM) that fine-tune H1 affinity for DNA
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and mediate H1 interactions with other proteins (297). Multiple H1 serine and threonine
phosphorylation events correlate with mitotic chromosome condensation (298) , whereas
individual H1 PTM affect the interactions between H1 and RNA polymerases near active
genes (299). Additional PTM in H1, including lysine methylation and acetylation, are
known but their functions have not been as thoroughly examined (297).
A remarkable histone PTM that is induced in neutrophil granulocytes in response
to inflammatory stimuli is the conversion of specific arginines to citrullines (202, 203).
The conversion is mediated by peptidylarginine deiminase (PAD4) (300, 301), an
enzyme that is required for the release of neutrophil extracellular traps (NETs) (213,
302). NETs consist of chromatin fibers that associate with components of the
neutrophils’ vast armamentarium of bactericidal substances (244). NETs presumably
serve to enmesh bacteria and yeast pathogens and surround them with compounds that
reduce their viability (194). Neutrophils from mice deficient in PAD4 are unable to
produce NETs and, as consequence, the animals suffer more serious bacterial infections
(213). Although core histones are prominent components of NETs, it has been
controversial whether H1 histones associate with NETs (194, 244).
Recently, we observed that certain human autoimmune sera contain
autoantibodies to deiminated core and linker histones (303). Therefore, we screened
additional autoimmune sera and identified autoantibodies that recognize the deiminated
human H1.2 histone. We used the antibodies to map the reactive H1 epitope and we
surveyed expression of H1 subtypes in neutrophils by RNA expression, H1 purification
and mass spectrometry. Purified H1 were subjected to LysC protease cleavage and
citrulline mapping by MS/MS. We observed H1 deimination in activated neutrophils and
increased immunoreactivity of one H1-reactive serum with activated neutrophils and
NETs. The data argue that neutrophil activation and NET chromatin release provide
circumstances for H1 extracellular release and stimulation of H1-reactive B cells. This
observation, along with other published studies, suggests that NETs are a source of
nuclear antigens that could stimulate autoreactive B cells.
Materials and Methods
Patient Serum Samples
Serum samples were collected at Institut de Biologie Moléculaire et Cellulaire;
Strasbourg, France and the University of Lubeck, Germany. In all, 24 SLE, 20 Sjögren’s
Syndrome, 20 Scleroderma and 20 RA serum samples were tested. All patients fulfilled
the American College of Rheumatology classification criteria for SLE (272), SS (304)
and Scl (305). This study was done in accordance with the IRB approvals from the
University of Tennessee, US, Institut de Biologie Moléculaire et Cellulaire; Strasbourg,
France and the University of Lubeck, Germany.
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In-vitro Deimination of Recombinant H1.2
Recombinant human histone H1.2 (Axxora) , were dissolved in PAD4 reaction
buffer (100mM HEPES, 100mM NaCl, 10mM CaCl2, 0.1mM EDTA and 2mM
Dithiothreitol) to a final concentration of 0.1 mM. The reaction mixture was incubated
for 10 min at 37°C and then recombinant PAD4 was added to a final concentration of 0.2
µM (274). Deimination was tested by Western blot using antibody to chemically
modified citrullines (Millipore) as per manufacturer’s instructions.
Western Blot
For Western blot analysis, proteins were resolved on 15% SDS-PAGE and
transferred to nitrocellulose as previously described (303). Membranes were blocked in
5% BSA, 0.1% Tween 20 in TBS overnight at 4°C. Next day, the membranes were
incubated with patient sera at 5 µg/ml of IgG in TBS containing 2.5% BSA, 1% NP-40
and 0.1% SDS using pre-blocked polyethylene pouches. After 2 h of incubation,
membranes were washed with 1% NP-40 in TBS. Anti-human IgG –HRP was used for
detection at 1:40,000 in 0.05% Tween 20 in TBS for 1 h and blots were developed using
“Western Lightning” chemiluminescence reagent (PerkinElmer). For Western blots of
human neutrophil extracts, cell lysates were prepared as described (202). Protein
concentration of lysates was measured in a Nanodrop 1000 spectrophotometer (Thermo
Scientific, Wilmington, Del., USA) and equal loading of the samples was confirmed by
Coomassie blue staining. For competition assay, synthetic peptides, competitor 1
(KKAGGTP-Cit-KASGPPVS) with arginine 32 of H1.2 replaced with citrulline, and
competitor 2 (KAVAASKE-Cit-SGVSLAA) with arginine 53 of H1.2 replaced with
citrulline were kind gift from Dr. Jean-Paul Briand of Institut de Biologie Moléculaire et
Cellulaire, Strasbourg, France. The peptides were incubated for 1h with a dilution of
SLE6 serum (5ug/ml of IgG) before the mixture was used for a Western blot.
Preparation of Protease Digested Peptides
Approximately 1.5 µg of the recombinant Histone H1.2 was desalted using a 3000
kDa MW cut-off centrifugal filter device (Millipore) according to the manufacturer’s
instructions. Protease digestion of H1.2 was performed overnight at 37°C with 50ng of
LysC and the digestion was stopped with the addition of TFA (1%, v/v). The solution
was dried in a Vacufuge Concentrator (Eppendorf, Westbury, NY, USA), and the dried
pellet was reconstituted in 20 ul of 0.1% TFA solution. The lysC digested peptides were
loaded on a C18 Ziptip column (Millipore), washed with 0.1% TFA and eluted with 10 µl
of a 50% acetonitrile solution. The eluant was near-dried in a vacufuge, and the residue
was reconstituted in 4 µl of a 0.1% formic acid solution. Two µl of that solution were
used for the LC/MSMS analysis.
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Liquid Chromatography-Mass Spectrometry and Database Search
The H1.2 peptides were resolved by HPLC by a gradient elution in which the
buffer changed from solvent A (0.1% formic acid solution) to solvent B (0.1% formic
acid in 90% methanol solution). Peptide masses were determined by using a Q-TOF
mass spectrometer in a positive-ion mode. The nano electrospray ionization source
temperature was set at 90ºC with capillary and cone voltage set to 3.0 kV and 30V
respectively. Mass calibrations were done using polyalanine (Michrom Bioresources
Inc., Auburn, CA, USA). Double- and triple-charged precursor ions with a count ≥ 20
were selected to perform MSMS. MSMS scans (5 second) were followed by an MS scan
(1 second). Masslynx software (version 3.5) was used to process the chromatographic
and mass spectrometric data. To identify proteins, Swissprot and NCBInr databases were
searched using Bioworks (version 3.2; Thermo-Fisher) and Mascot (web-version)
software. The precursor ion (MS) and product-ion (MSMS) mass-error tolerances were
both set to 0.1 Da. The modification of arginine was set to 0.98 Da because the
monoisotopic mass difference between citrulline (C6H13N3O3) and arginine (C6H14N4O2)
is 0.98 Da.
RNA Extraction and Microarray Analysis
Total mRNA was isolated from neutrophils using RNeasy Mini Kit (Qiagen) as
suggested by the manufacturer. Genomic DNA was eliminated by RNase-free DNase I
(Qiagen) digestion during the isolation procedure. Isolated total RNA was analyzed on an
Agilent 2100 Bioanalyzer using RNA 6000 Pico Labchip Kit (Agilent Technologies).
Reverse transcription to cDNA was performed at 50°C for 1 h followed by 85°C for 5
min with Transcriptor First Strand cDNA Synthesis Kit (Roche) using random hexamer
and anchored-oligo (dT) primers (Roche). RNA quantitations were performed using the
Whole-Transcript Human Gene 1.0 ST array (Affymetrix).
Neutrophil Isolation and Stimulation
Neutrophils were isolated from healthy donor blood purchased from Keybiologics
(Memphis, TN) and used in accordance with protocols approved by the Institutional
Review Board (IRB), University of Tennessee. Neutrophils were isolated as described
(202). Briefly, neutrophils were enriched using dextran sedimentation and recovered
from an isolymph density gradient (Gallard-Schlesinger, Plainview, N.Y, USA) under
endotoxin-free conditions. Erythrocytes were lysed in ice-cold, hypotonic buffer (0.2%
NaCl) for 30 s, and lysis was stopped by adding hypertonic saline (1.6% NaCl).
Neutrophils were suspended in HBSS (without Ca++ or Mg++) with 0.1% glucose and
0.5% heat-inactivated human serum or in HBSS with 0.5% heat-inactivated human serum
at a final concentration of 2 X 106 neutrophils/ml. Neutrophils were stimulated with
ionophore in HBBS containing 2mM Ca++ at 37°C for 2 h. Following incubations,
neutrophils were pelleted and lysed in SDS-lysis buffer (2% SDS in 62.5mM Tris, pH
6.8, supplemented with 5% 2-ME and 10% glycerol).
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Linker Histone H1 Extraction and Purification
Perchloric acid extraction of H1 was performed as described earlier (297).
Briefly, 50 million neutrophils were resuspended in 0.5ml of 5% HClO4 and subjected to
three cycles of freezing (in mix of dry ice and methanol), thawing at 37°C and vortexing
(10 s). The final suspension was centrifuged at 15,000 × g for 10 min. The clear
supernatants were mixed with an equal volume of ice-cold 66% (v/v) CCl3COOH. The
linker histones were precipitated for 30 min on ice and collected by centrifugation at
15,000 × g for 10 min. The pellets were washed with 0.2% HCl in acetone, then twice
with pure acetone, and vacuum-dried. The dried pellets were reconstituted in high salt
buffer (25mM HEPES pH 7.6 with 550mM NaCl, 12.5mM MgCl2 and 0.1mM EDTA).
Confocal Microscopy
Neutrophils were isolated as described above and allowed to settle for 30 min
onto a poly-L-lysine coated glass coverslips as described (202). Cells were treated with
LPS (100 ng/ml) for 1 h at 37°C. Coverslips were washed with ice cold HBSS, cells
were fixed with 4 % paraformaldehyde in HBSS for 15 min at room temperature and
incubated overnight with blocking buffer (HBSS with 10% FBS, 1% BSA, 0.05% Tween
20 and 2mM EDTA) at 4°C. The coverslips were washed with wash buffer (HBSS with
3% FBS) and incubated with patient serum (20 µg/ml IgG) or rabbit Abs that bind
citrullines in the N terminus of histone H3 (Abcam, Cat # ab5103; 1:100 dilution) in
wash buffer at 4°C for 1 h. Coverslips were washed and incubated with AF647conjugated goat anti-human IgG, AF488-conjugated goat anti-rabbit IgG and Sytox
Orange (all from Invitrogen) for 30 min at 4°C. Coverslips were washed and mounted on
glass slides using mounting media (wash buffer with 50% glycerol) and analyzed by
confocal microscopy.
Results
Identification of Autoantibodies to Deiminated H1.2
Previously, we identified autoantibodies to deiminated core and linker histones
(303). Because deimination of linker histones has not been characterized, we screened 24
additional SLE sera, 20 Sjögren’s syndrome sera, 20 scleroderma sera, and 20
rheumatoid arthritis sera for antibodies with preference for deiminated H1 histones
(representative results are shown in Figure 3-1A). As antigen, we used recombinant
human H1.2 that was treated with PAD4 in vitro or left untreated. In all, 72 sera
contained anti-H1 antibodies, as assessed by Western blot, and 4 sera bound deiminated
H1.2 with at least 2-fold preference over non-deiminated H1.2. However, the vast
majority of patient sera showed comparable binding to either form of H1.2 and no serum
showed a bias toward the non-deiminated H1.2. We may have missed some
autoantibodies to deiminated linker histones because we did not measure binding to all
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Figure 3-1: Preferential binding of autoimmune sera to deiminated H1.2
Equal amounts of non-deiminated (H) and deiminated (C) H1.2 were blotted on
nitrocellulose and probed with sera from systemic lupus erythematosus, Sjögren’s
syndrome, scleroderma and rheumatoid arthritis patients. Five representative blots from
each set are shown. The ratio of binding to deiminated vs. non-deiminated H1.2 (C/H)
was calculated with ImageJ software and values are listed below each blot. Two sera
each of SLE and Sjögren’s syndrome showed a greater than 2.0 binding preference for
deiminated H1.2 (A). Equal amounts of non-deiminated (H) and deiminated (C) H1.2
and BSA were analyzed by coomassie staining or probed with SLE6 serum. Preferential
binding of SLE6 to deiminated H1.2 over non-deiminated H1.2 and no detectable binding
to deiminated BSA reveal the contribution of deiminated residue(s) and adjoining protein
sequence as determinants of the specificity of SLE6 IgG (B).
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H1 subtypes whose unique epitopes may represent additional autoantibody targets (296).
In the following experiments, we used the SLE6 serum (303) whose binding was highly
biased toward deiminated H1.2 and did not extend to citrullines in a heterologous protein
(BSA; Figure 3-1B).
Determination of Autoepitope in Histone H1.2
Because SLE6 antiserum preferentially bound deiminated histone H1.2, we asked
whether one of the 3 arginines in H1.2, if converted to citrulline, formed the SLE6
binding determinant. We addressed the question by using synthetic peptides as inhibitors
of antibody binding. To compete binding of SLE6 to the deiminated histone H1.2, we
incubated the serum with either of two peptides (containing citrulline at position 32 or at
position 53 of H1.2; Figure 3-2A) before reacting the serum against the intact histones
on a Western blot (Figure 3-2B). Dilutions of the 16-mer peptides were prepared and
their effect on binding to the immobilized histones was compared. The preference of
SLE6 for deiminated H1.2 was maintained even after incubation with 1.0 ug of
Competitor 1 (KKAGGTP-Cit-KASGPPVS), whereas, in a parallel incubation,
preferential binding was eliminated with a ten-fold lower amount of Competitor 2
(KAVAASKE-Cit-SGVSLAA). Thus, we concluded that Competitor 2, containing
citrulline in place of arginine 53, was more effective as inhibitor of SLE6 binding and
therefore shared structural features with the authentic H1.2 autoepitope recognized by the
SLE6 serum autoantibodies.
Deimination of Recombinant H1.2
To confirm that incubation of H1.2 with PAD4 converts arginine 53 to citrulline,
we subjected the deiminated H1.2 to Lys C protease cleavage and analyzed the peptides
by MS/MS. We also asked if arginine 32 and 78 of H1.2 serve as substrates for PAD4
deimination. We observed multiple peptide fragments (including the b2 and y9 ions;
Figure 3-3A) that were consistent with arginine deimination occurring within the amino
terminal dipeptide of ER*SGVSLAALK. In addition, we identified citrulline at position
32 of H1.2 by performing MS/MS on the peptide AGGTPR*K (Figure 3-3B). The mass
determination using Q-TOF spectroscopy was consistent with the presence of citrulline
(1130.70 Da for the LysC-derived peptide, compared to the theoretical monoisotopic
masses of 1129.65 and 1130.63 Da for the unmodified versus the deiminated peptides).
To estimate the uncertainty inherent in the measurements, the experiment was performed
three times and each time the error was less than 62 ppm. Thus, the mass measurements
proved reliable and sufficient to discriminate between arginine and citrulline in this
peptide. In contrast, we observed that the NNSRIK peptide was resistant to deimination,
inasmuch as we did not detect citrulline within that peptide even after a 4 h incubation
with recombinant PAD4 (Figure 3-3C).
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Figure 3-2: Peptide inhibition of SLE6 binding to deiminated H1.2
The preferential binding of SLE6 to deiminated H1.2 was assessed after a preincubation
of the serum in the presence of either of two 16mer synthetic peptides (Competitor 1=
R32Cit; KKAGGTP-Cit-KASGPPVS) and Competitor 2= R53Cit; KAVAASKE-CitSGVSLAA). The peptides were designed to match H1.2 with citrulline residues
substituting for arginine 32 or 53 (A). Equal amounts of deiminated (C) and nondeiminated (H) H1.2 were analyzed by SDS-PAGE (Coomassie) or blotted and probed
with SLE6 serum. Panels below the horizontal line show results of Western blot
performed following a preincubation in the presence of competitors 1 or 2. The mass of
the peptide is indicated beneath each panel. Competitor 2 (R53Cit) was more effective at
blocking preferential binding of SLE6 to deiminated H1.2 (B).
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Figure 3-3: MS/MS analysis of in vitro deiminated recombinant H1.2
MS/MS spectra of doubly charged precursor ions of deiminated histone H1.2 treated with
LysC protease to release peptides (A-C). Fragmented ions (b series and y series) are
marked on respective peptide sequences and on the MS/MS spectra. Two of 3 arginines
in H1.2, peptide ER*SGVSLAALK (A) and AGGTPR*K (B) showed mass consistent
with deimination to citrulline. We found no evidence for peptide NNSRIK (C)
deimination during the in vitro PAD4 reaction.
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Autoimmune IgG Preferentially Bind H1 Linker Histones in Activated Neutrophils
and Neutrophil Extracellular Chromatin
To assess the range of SLE6-reactive proteins on Western blots, we prepared total
cell lysates from unstimulated and Ca-ionophore stimulated human neutrophils. Lysates
were resolved on SDS-PAGE, blotted onto nitrocellulose membranes and probed with
SLE6 serum (Figure 3-4A). Antibodies bound numerous proteins from both Ca++
ionophore treated and untreated neutrophils, with notably little to no detectable binding to
core histones. Binding of SLE6 to lysates showed that a protein in the molecular weight
range of histone H1 along with few other proteins became more immunoreactive
following treatment with Ca++ ionophore (Figure 3-4A).
To examine the distribution of SLE6 antigen targets in cells, we stimulated
neutrophils with LPS, an inflammatory stimulus that induces deimination and chromatin
release from neutrophils (202), and used them for confocal microscopy. LPS-treated and
untreated cells were incubated with SLE6, as well as a rabbit antibody to deiminated H3
and the DNA stain sytox orange (Figure 3-4B-D). SLE6 IgG binding increased in LPStreated neutrophils with decondensed chromatin (Figure 3-4C), whereas unstimulated
neutrophils maintaining a lobed nuclear architecture showed minimal IgG binding
(Figure 3-4B). In contrast, SLE6 IgG colocalized with deiminated H3 in decondensed
intracellular chromatin (Figure 3-4C) and in some neutrophil NETs (Figure 3-4D).
Intense granular SLE6 staining was observed in the cytoplasm of activated neutrophils,
suggesting segregation of immunoreactive epitopes from the nuclear compartment before
chromatin release (Figure 3-4D).
Neutrophils Express Multiple H1 mRNAs and Proteins
To obtain a more complete view of H1 subtype expression in neutrophils, we
isolated total RNA from blood neutrophils and examined the representation of different
H1 mRNA by hybridization to expression microarrays (Figure 3-5A). H1.4 was the
most actively transcribed linker histone, followed by H1.0 and H1.2. In contrast, H1.1,
H1.3 and H1.5 expression was near background levels (Figure 3-5A). The expression
levels of the house-keeping gene, HGPRT were similar in magnitude to histone H1.2
(Figure 3-5A). These data indicate that mature neutrophils express a limited set of linker
histones and that the bulk of newly made histones is comprised of H1.4.
Next, we asked whether the RNA present in mature neutrophils reflects the H1
protein complement that is present in neutrophils. For that purpose, we compared
untreated human neutrophils to neutrophils stimulated with A23187 calcium ionophore
for 2 h. The H1 proteins were isolated from treated and untreated neutrophils by 5%
perchloric acid extraction, separated by gel electrophoresis and probed with anti-citrulline
antibodies (Figure 3-5B). H1 isolated from ionophore-treated cells reacted with the
antibodies, indicating the presence of citrullines. In addition, the purified H1 resolved
into a set of similar-sized proteins, suggesting the expression of different H1 subtypes.

56

Figure 3-4: Neutrophil activation increases SLE6 reactivity
Lysates of unstimulated (U) and Ca++ ionophore-treated (S) neutrophil were probed with
SLE6 serum (A). Enhanced binding of IgG to a doublet of proteins migrating to a
position near the 37kD marker is indicated (arrow). SLE binding (red) to unstimulated or
LPS treated neutrophils was compared to the binding of anti-deiminated H3 antibody
(green) and the DNA binding dye, sytox orange (blue) (B-D). Faint SLE6 binding to the
cytoplasm of untreated neutrophils (B). SLE6 binding is increased in LPS-treated
neutrophils that have lost the integrity of nuclear membrane (C) and show increased
reactivity with the anti-deiminated H3 antibody (C). SLE6 bound to NETs that reacted
with the anti-deiminated H3, although prominent cytoplasmic clusters of SLE6 binding
were also observed (D).
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Figure 3-5: Analysis of linker histone transcripts and proteins from neutrophils
Relative mRNA levels of different H1 subtypes were determined from total mRNA
extracted from neutrophils. cDNA was prepared by reverse transcription and expression
levels were measured on an Affymetrix Whole-Transcript Human Gene 1.0 ST Array.
Relative fluorescence intensities were plotted for each H1 subtype (A). Whole cell
lysates and perchloric-acid-extracted linker histones from unstimulated (U) and Ca++
ionophore-stimulated (S) neutrophils were analyzed by SDS-PAGE (coomassie).
Extracted H1 histones were blotted, chemically modified and probed with anti-Cit
(modified) antibody. Only H1 from activated neutrophils reacted with the antibody (B).
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MS/MS Analysis of H1 Histones from Activated Neutrophils
Following LysC digestion of H1 from activated neutrophils, mass spectroscopy
identified the ER*SGVSLAALK peptide that may derive from H1.2, H1.3 or H1.4 (296).
To confirm that the deimination of arginine to citrulline is consistent with the predicted
peptide sequence, we performed MS/MS of the product-ions exclusively on the precursor
ER*SGVSLAALK peptide (Figure 3-6A). The MS/MS spectrum contained a series of
y-ions (y1-y9) that did not contain R*. However, the b-series ions (b2-b10) exhibited
masses consistent with citrulline: the b2# (b2-NH3), b4@ (b4-H2O), and b10 ion were found
at m/z 270.11, 413.21, and 985.60, respectively. The mass errors were 0.02, 0.03, and
0.07 Da, respectively for an average error of 0.04 Da. Therefore, the masses of all the bions closely matched the masses that are predicted by the presence of citrulline instead of
arginine at position 53 of H1.2 (Figure 3-3A). Similar arguments apply to the
homologous peptide that was derived from histone H1.5 (ER*NGLSLAALK, Figure
3-6C), in that masses corresponding to the b3, b7, b8, b9 and b10 ions closely matched
those that are predicted if citrulline replaces arginine.
Interestingly, the H1 histones that were purified from activated neutrophils also
yielded peptides that were identical to the ones described above except for the presence
of arginines (Figure 3-6B and D). There, the b and y series ion masses were consistent
with the presence of arginine, indicating that a 2 h treatment of neutrophils with
ionophore does not completely convert histone H1 arginines to citrullines. Moreover, we
observed the deimination of arginines in unique peptides derived from histone H1.0:
GVGASGFR*LAK (Figure 3-6E) and R*LVTGVLK (Table 3-1). In contrast, we found
no evidence for deimination of the arginine in NNSRIK that is part of the third helix in
the globular domain (Figure 3-6F). Our results suggest that several arginines in the
globular DNA binding domain of H1, including R53, the most conserved arginine in H1
histones, are converted to citrulline following neutrophil activation (Table 3-1).
Summary of Histone H1 Expression in Neutrophils
The mass spectrometry experiments provided evidence supporting the expression
of at least 5 different H1 proteins in neutrophils. We identified peptides whose sequences
unambiguously matched unique sequences in each of 5 different H1 subtypes (H1.0,
H1.2, H1.3, H1.4 and H1.5; see Figure 3-7). It is interesting that we detected a peptide
matching H1.3 (VAGAATPK) and two peptides matching H1.5 (KPAGATPK and
KPAAAGVK), despite very low mRNA for H1.3 and H1.5 (Figure 3-5A). Overall,
protease cleavage and mass spectrometry yielded a sequence coverage of 30-44% for
each of the H1 proteins, although some peptides were shared between the most closely
related H1 subtypes (Figure 3-7).
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Figure 3-6: MS/MS analysis of H1 peptides from activated neutrophils
MS/MS spectra of peptides yielding doubly charged precursor ions of H1 histone from
Ca++ ionophore treated neutrophils (A-F). Fragmented ions (b series and y series) are
marked on the peptide sequences or spectral peaks. Both peptide ER*SGVSLAALK (A)
and ERSGVSLAALK (B) were observed, with a +1Da shift resulting from deimination
of arginine in evidence in b2 and b10 ions. The peptide ERSGVSLAALK is conserved
between H1.2, H1.3 and H1.4 subtypes. Both ER*NGLSLAALK (C) and its
non-deiminated form ERNGLSLAALK (D) derived from H1.5 were identified. Again,
the mass shift of corresponding b ions is consisten with arginine deimination. Argininecontaining peptide GVGASGFR*LAK (E) from H1.0 was also identified, whereas
peptide NNSRIK (F), conserved in subtypes H1.1-H1.5 was only found in its
non-deiminated form.
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Table 3-1:
neutrophils

Arginine containing peptides detected in H1 extracted from activated

Deiminated Peptides

Non-modified Peptides

Corresponding H1 Isotype

ER*SGVSLAALK

ERSGVSLAALK

H1.2 – H1.4

ER*NGLSLAALK

ERNGLSLAALK

H1.5

GVGASGFR*LAK

-

H1.0

R*LVTTGVLK

-

H1.0

-

NNSRIK

H1.1 – H1.5

* Indicate deimination of arginine to citrulline.
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Figure 3-7: Summary of mass spectrometry with linker histones from activated neutrophils
Sequences of somatic linker histone H1 subtypes were aligned to maximize homology. Arginine residues are indicated in red. Peptides
identified by mass spectrometry highlighted in yellow, and H1 subtype-specific peptide sequences are in black and underlined. The
globular domain of H1 is indicated by a broken line above the sequences. Brown boxes represent the 3 helices of the H1 winged helix.
Residues contributing to DNA binding residues are indicated with arrows.
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Discussion
Evidence mounts that NETs participate in the induction of autoimmune responses.
Because NETs are released at sites of inflammation (306-309) and NET chromatin
intimately associates with bacteria (194, 310), NETs were predicted to contribute to
autoimmunity (285). Recent observations support this prediction. Autoantibodies from
patients with systemic autoimmunity recognize innate immune defense proteins that
associate with NETs. This is the case for the major NET components, including the
granule proteases elastase, cathepsin G and proteinase 3 (235, 236, 238), as well as for
various bactericidal peptides that are stored in granules and co-purify with NETs, such as
neutrophil defensins and the LL37 peptide (239, 240). Therefore it is relevant to further
characterize mechanisms involved in the release of NET chromatin.
NET release depends on PAD4 (213, 302). Although PAD4 deiminates a variety
of substrates (283, 303), it is plausible that histone deimination plays an important role in
the unfolding of nuclear chromatin into the extended structure of NETs. Consistent with
this role, treatment of a nucleosome array with PAD4 decreased its capacity for
compaction in the presence of linker histone H5 (311). Our studies have revealed that
NETs contain deiminated histones (202). Deiminated histones thus can be considered as
markers of NET chromatin (312, 313).
In that light, our recent studies support the idea that NETs induce autoantibody
responses in susceptible individuals. We screened sera from patients with SLE, RA and
Felty’s syndrome and found examples of sera that preferentially bound to deiminated
histones (303).
Our current results confirm that human autoimmune IgG react with the
deiminated form of human H1.2. Autoantibodies to deiminated histone H1 provide
support for the hypothesis that NETs induce autoantibodies. However, only a small
fraction of the tested sera (5%) had antibodies with a marked preference for the
citrullinated form of H1. Antibodies to linker histones H1 are considered as important
marker SLE as dsDNA. Detection of antibodies against H1 by ELISA yield a sensitivity
of about 45% with a specificity of 98% in diagnosing SLE (314). H1 antibodies show a
strong association with disease activity such as lupus nephritis (314) and neuropsychiatric
lupus (315). H1 is also an important autoimmune target in Sjögren's syndrome as binding
of purified IgG against an immunodominant epitope of La/SSB antigen was completely
inhibited by H1 (316). Involvement of H1 in lupus is not limited to being an
autoimmune target. PBMCs co-cultured with H1 from lupus patients, but not healthy
controls, induced increased production of TNF-alpha (317). Whether antibodies to
deiminated H1 derive from a subset of patients with particular clinical features is
unknown.
Our results identify the complement of H1 subtypes expressed in human
neutrophils. Although the H1.4 gene encodes the majority of mRNA in mature
neutrophils (Figure 3-5A), neutrophils contain at least five H1 subtypes (Figure 3-7),
including H1.3 and H1.5 for which very little if any mRNA could be detected. This
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observation suggests that H1.3 and H1.5 may be synthesized during neutrophil
development but that they are replaced with H1.0, H1.2 and particularly with H1.4 as
neutrophils mature. Because H1 histones play important regulatory roles in chromatin
compaction (296), it is likely that changes in H1 subtype expression reflect changes in
chromatin conformation, condensation, or nuclear morphology. A shift in subtype
expression may alter global chromatin properties because different H1 subtypes differ in
their DNA binding and/or protein interaction potential.
The binding of SLE6 serum IgG to an epitope containing citrulline at position 53
of the H1 winged helix was surprising because the arginine at position 53 was considered
to be a DNA binding residue (318). DNA bound to arginine 53 may shield this domain
of histone H1 from antibody binding. Moreover, arginine 53 is conserved in all human
H1 subtypes and is located within the structurally conserved globular region of H1
(Figure 3-7). However, the involvement of R53 in DNA binding was deduced from
mutagenesis of this arginine in histone H1.0 (318). A recent study which examined this
residue in H1.2 found only a negligible effect of an alanine substitution on DNA binding
(319). The authors suggested that the 53 position is not part of the DNA binding site and
that their result may explain why H1.0 binds more tightly to DNA than H1.2 (319). This
result may imply that H1.2 has only two DNA binding sites, whereas H1.0 has three.
If that conclusion holds true, then R53 must have another function that is highly
conserved in evolution. It could be that R53 contributes to one or more of the protein
interactions that have been identified for H1 histones. These range from interactions with
core histones in chromatin (320) to interactions with RNA polymerase (299) and various
transcription factors (321, 322). Because the two main H1 subtypes that are expressed in
mature neutrophils, H1.2 and H1.4, may not use R53 for DNA binding, it may be that this
residue has an important role in the specific nuclear chromatin changes that take place in
neutrophil activation.
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CHAPTER 4.

DEIMINATION REDUCES REACTIVITY OF HISTONES WITH
MURINE LUPUS AUTOANTIBODIES
Summary

Deimination of histones, a posttranslational modification of arginine to citrulline
by peptidylarginine deiminase 4 (PAD4), is associated with neutrophil extracellular traps
(NETs) and may compromise tolerance of self-antigens. The aim of this study was to test
whether spontaneously autoimmune mice react preferentially with deiminated or nondeiminated histones.
IgG Ab binding to deiminated histones and non-deiminated histones were
determined by ELISA and Western blotting, and splenocyte proliferation was analyzed in
spontaneously autoimmune mice. We measured levels of deiminated histones in tissues
from C57BL/6.Sle1.Sle2.Sle3 (B6.TC) and control mice, to search for putative
tolerogens. Serum IgG from autoimmune (NZBxNZW)F1, NZM2410, and
C57BL/6.Sle1.Sle3 mice consistently bound non-deiminated histones with preference
over deiminated histones. In contrast, splenocytes from (NZBxNZW)F1 proliferated with
no bias for either antigen. In addition, the bone marrows and spleens of B6.TC mice
contained increased amounts of deiminated histones as compared to control C57BL/6
mice.
Our study demonstrates that sera of autoimmune lupus prone mice react less
strongly against deiminated histones than non-deiminated histones. We note that
deiminated histones, presumably derived from NETs, are available at increased levels in
primary and secondary lymphoid tissues of autoimmune mice relative to littermates. The
deiminated histones may function as tolerogens to suppress production of anti-deiminated
histone IgG.
Introduction
Connections between the innate and adaptive immune system are intriguing and
often surprising. This is particularly true with regard to mechanisms that distinguish self
from non-self (323). A special challenge for adaptive immunity arises during neutrophil
responses to infections. Neutrophils respond to bacterial infections by ejecting nuclear
chromatin from the confines of the cell (194). The chromatin is associated with various
bactericidal substances and it forms a mesh that immobilizes infectious organisms (324).
These structures are called neutrophil extracellular traps (NETs). NETs serve to capture
bacteria and fungi. It is important to efficiently clear NETs, as they can promote
intravascular thrombosis (307).
The challenge for the adaptive immune response is to use the NET-ted bacteria as
antigens, while maintaining tolerance to the structural components of NETs. A possible
confounding factor in the recognition of NETs may be that their release is accompanied
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by a particular post-translational modification (PTM). Neutrophils exposed to
inflammatory stimuli, or the physical proximity of microbes, induce the enzyme
peptidylarginine deiminase 4 (PAD4) which converts arginines to citrullines (202).
Deimination of histones appears to play a special role in the release of NETs, as
mice deficient in PAD4, the enzyme that deiminates histones, fail to make NETs and
suffer more serious infections (213). Deimination may have broader physiological roles
and yet several deiminated self-proteins are targeted by autoantibodies. Deimination of
keratin and filaggrin occur during terminal differentiation of keratinocytes (209, 210,
325) yet deiminated filaggrin is a target of antibodies (Abs) associated with rheumatoid
arthritis (RA) (214). Generally, anti-citrullinated protein antibodies (ACPA) serve as
reliable diagnostic markers for RA (326). Deimination of vimentin, a member of the
intermediate filament family of cytoskeletal proteins, generates the target of anti-Sa
autoantibodies in RA (264). It is not clear whether normal levels of deimination generate
autoepitopes in RA or whether the deimination in RA is enhanced and produces unusual
“neo” epitopes.
PAD4 is the only PAD that has a nuclear localization signal and deiminates
histones H2A, H3, and H4 (268, 327). In a genetic study, a link between PAD4 and RA
was observed: Haplotypes linked to increased RA susceptibility produced PAD4 mRNA
that was more stable than mRNA from non-susceptible haplotypes (228). The increased
mRNA stability may lead to increased expression of PAD4 in individual carriers of these
susceptibility haplotypes. The association between deiminated proteins and various
autoimmune diseases strongly suggests that deimination generates novel epitopes that are
able to break tolerance and initiate autoimmune responses. However, it is not known
whether deimination of histones is sufficient to break tolerance to nuclear autoantigens.
Recently, it has been suggested that NETs are responsible for inducing
autoimmune reactions (242, 328, 329). Type 1 IFN, involved in lupus pathogenesis, has
been found to prime neutrophils to release NETs (328). Consequences of NET release
are exposure of DNA-peptide complexes (242) that cause further release of Type 1 IFN
from plasmacytoid dendritic cells (329). Also, the structural components of NETs and
various associated proteins and peptides have been recognized as autoantigens in lupus
patients (260, 330, 331). Based on these facts and our observation that chromatin
released in NETs consist of deiminated histones, we investigated the hypothesis that if
NETs are induced by inflammation, as is typical of autoimmunity, and if NETs are
immunogenic, then anti-deiminated histone antibodies should be prevalent in lupus-prone
mice.
IgGs from (NZBxNZW)F1 mice and their recombinant derivative strains,
including NZM2410 and B6.Sle1, B6.Sle1.Sle3 or B6.TC congenics, showed strong
preference for non-deiminated histones over deiminated histones by ELISA and Western
blot. Thus, even after tolerance to histones was broken and autoantibodies to nondeiminated histones were expressed, autoimmune-prone congenic strains remained
tolerant of deiminated histones. B cell binding to deiminated histones relative to nondeiminated histones was reduced. Therefore, autoantibody binding focused on PAD4
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substrate arginines. No such bias was observed with autoreactive splenocytes from
autoimmune (NZBxNZW)F1 mice. These splenocytes responded differentially to
deiminated histones versus non-deiminated histones and the responses developed
simultaneously with serum anti-DNA autoantibodies. The splenocyte response was
idiosyncratic in preferentially targeting either deiminated histones or non-deiminated
histones. The B cell bias against deiminated histones argues that deiminated histones
remain effective tolerogens in autoimmune mice. In support of this possibility, we
observed elevated levels of deiminated histones in bone marrows and spleens of
autoimmune B6.TC mice. Our observations suggest that, even in overtly autoimmune
lupus mice, tolerance mechanisms inhibit B cells that react with a deiminated variant of
an important nuclear autoantigen.
Methods
In-vitro Histone Deimination
Calf thymus histones (US Biochemicals) were dissolved in PAD4 reaction buffer
(100 mM Tris-HCl at pH 7.6, 50 mM NaCl, 2 mM DTT and 10 mM CaCl2) to a final
concentration of 0.1 mM total histones. The reaction mixture was incubated for 10 min
at 37°C and then PAD4 enzyme was added to a final concentration of 0.2 µM to start the
reaction. Sixty µl aliquots were taken at different time points and the reaction was
quenched with liquid nitrogen. Amounts of deiminated proteins were estimated by
colorimetry as described (332) using L-citrulline (Sigma) as a standard. Deimination was
also confirmed by Western blot using anti-deiminated histone antibody from Abcam
(Cat # ab5103) that recognizes citrullines at positions 2, 8, and 17 of histone H3.
Immunization of Mice
Experiments were performed on 4-6 week female BALB/c mice housed in the
animal care facility of the University of Tennessee Health Science Center, Memphis
USA. All experimental protocols were reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC). BALB/c mice were divided into different
groups for immunization. Four mice each were immunized intraperitoneally with 100 µg
of non-deiminated histones or deiminated histones. Two mice were immunized with 100
µg of ovalbumin (OVA) as a positive control. Initial immunizations were done with
emulsified proteins in complete Freund’s adjuvant (CFA) and one subsequent
immunization was done in incomplete Freund’s adjuvant (IFA). Mice were boosted 10
days after the first immunization, and sera were collected 7 days later and used for
comparison in ELISA. In addition, two mice each from the deiminated histone and nondeiminated histone groups were boosted with 100 µg of deiminated histone or nondeiminated histone and 20 µg of Imiquimod (Invivogen), a TLR-7 stimulant, along with
IFA. The remaining two mice from each group were boosted with 100 µg of deiminated
histones or non-deiminated histones in IFA. One mouse from the OVA group was also
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boosted with 100 µg of OVA along with 20 µg of Imiquimod in IFA. Sera were analyzed
seven days after each immunization.
ELISA
Sera were obtained from (NZBxNZW)F1, NZM2410, B6.Sle1, B6.Sle1.Sle3 and
B6.TC mice at 7 months of age when these mice produce autoantibodies. The treatment
and care of animals were in accordance with the guidelines of the IACUC of UTHSC, the
University of Florida and the Norwegian Ethical and Welfare Board. Deiminated
histones for ELISA and Western blot were prepared in vitro. Deimination of nondeiminated histones (Calf thymus histones, US Biochemicals) was done by recombinant
PAD4 as described above. Flat bottom, 96 well microtiter plates (Immulon 4HBX;
Thermo Electron Corp.) were coated overnight with 5 µg/mL of deiminated histones,
non-deiminated histones, OVA (Sigma) or coating buffer alone (control). Plates were
washed 3 times with 0.05% Tween-20 in PBS and blocked with 2.5% BSA in 0.02%
NaN3 and PBS for 2 h. A 1:200 initial dilution of primary sera along with 5-fold serial
dilutions in 1.6% Tween-20 and 1% BSA in PBS were incubated for 2 h in plates. Then,
serum dilutions were removed and wells were washed with 0.1% Tween-20 in PBS.
Alkaline phosphate-conjugated goat anti-mouse IgG (γ-chain-specific; Southern Biotech)
was added at 1:1000 dilution in 1% BSA with 0.05% Tween-20 in PBS for 1 h.
Phosphatase substrate (Sigma) was used to develop the ELISA and OD values were read
at 405 nm on a Multiskan Plus plate reader (Labsystems).
ELISA with the sera from immunized BALB/c mice was done with the same
protocol as described in methods with a modification such that the initial serum dilutions
tested were 1:100 with 1:3 serial dilutions, whereas as initial serum dilutions for
autoimmune mice were 1:200 with 1:5 serial dilutions.
Serum antibodies against dsDNA were detected by ELISA exactly as described
(333, 334). In short, calf-thymus dsDNA (10ug/ml in PBS) was coated on microtitre
plates (MaxiSorb; Nunc, Copenhagen, Denmark). Sera from mice were diluted 2 fold
from 1:100 to 1:3,200 in PBS containing 0.02% Tween-20 and incubated in wells.
ELISA readings were obtained with peroxidase-conjugated rabbit anti-mouse Fc-γ
antibodies.
Western Blot
For Western blot analysis, proteins were resolved on 15% SDS-PAGE and
transferred to nitrocellulose. Membranes were blocked in 5% BSA in 0.1% Tween 20 in
TBS (TBST) overnight at 4°C. Subsequently, the membranes were incubated with sera at
1:500 dilution in TBS containing 2.5% BSA, 0.5% NP-40 and 0.05% SDS. After 2 h of
incubation, membranes were washed with 1% NP-40 in TBS. Anti-mouse IgG–HRP
(H+L-chain-specific; Millipore) was used for detection at 1:10,000 dilution in TBST for
1 h and blots were developed using “Western Lightning” chemiluminescence
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(PerkinElmer). Separately, autoimmune sera were treated with DNase1 prior to Western
blotting. Briefly, 400ul of a 1:200 dilution of sera were incubated with 20 units of
DNase1 (New England Biolabs) for 1 h at room temperature before adjusting the sera to a
1:500 dilution in Western blot binding buffer. To probe for deiminated histone H3 in
B6.TC and C57BL/6 mice, equal amount of tissue lysates were resolved on 12%
SDS-PAGE and transferred to nitrocellulose. Membranes were blocked with 5% BSA in
TBST for 30 min and incubated with anti-deiminated histone H3 rabbit antibody (Abcam,
ab 5103) overnight at 4°C. Membranes were washed and incubated with HRPconjugated goat-anti-rabbit secondary antibody for 1 h at room temperature, washed three
times in TBST and twice in TBS alone. The HRP activity was detected as above.
Splenocyte Proliferation Assay
BALB/c mice were boosted twice with 100µg antigen (deiminated histones,
non-deiminated histones or OVA) 14 and 2 days prior to the splenocyte proliferation
assay. Ninety-six well tissue culture plates (Corning Incorporated) were filled with 100
µl aliquots of 100 µg/ml (or 3 fold serial dilutions) of deiminated histones, nondeiminated histones, or ovalbumin in RPMI 1640 (Mediatech Inc.) supplemented with
10% FBS. Splenocytes were isolated and resuspended in RPMI with 10% FBS at 1x106
cells/ml. One hundred µl of cell suspension was added to each well and plates were
incubated at 37°C in 5% CO2 for 72 to 96 h. Tritiated thymidine (1 µCi/well) was added
for the last 17 h of incubation. Plates were harvested onto glass fiber filters and
thymidine incorporation was assessed by scintillation counting.
Splenocyte proliferation assays for autoimmune mice used splenocytes from
female (NZBxNZW) F1 mice of different ages purchased from the Jackson Laboratory
(Bar Harbor, ME). Following RBC lysis, splenocytes were resuspended in DMEM-10
media with 10000 U/ml penicillin and 10 mg/ml streptomycin. One hundred thousand
cells were incubated with deiminated histones or non-deiminated histones (20ug/ml of
protein) in triplicate wells. Tritiated thymidine incorporation (1 µCi/well) was measured
after 20 h, 3 days or 6 days by liquid scintillation, as described (335, 336).
Ex-vivo Tissue Lysate Preparation
Seven-month-old B6.TC female mice and age-matched control C57BL/6 IgHa
were dissected. A portion of spleen, bone marrow, kidney and liver was cut, minced with
scissors and crushed between two sterile frosted glass slides. Dissociated tissues were
washed in PBS (without Ca++) and centrifuged at 5000g for 5 min to pellet cells. Cell
pellets were mixed with lysis buffer (65mM Tris pH 7.2, 2%SDS, 10% Glycerol),
containing protease inhibitors. To test for deiminated histones and total H3 in tissue
lysates, equal amounts of total protein were analyzed by Western blotting, as described
above.
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Results
In-vitro Histone Deimination
For the immunization and immunochemistry experiments, we prepared calf
thymus deiminated histones by using recombinant PAD4 (274). The deimination
reaction reached completion by 24 h (Figure 4-1A), as addition of more PAD4 enzyme
to the reaction at that time did not increase deimination (data not shown). We measured
the generation of 1.67 moles of citrulline per mole of total histones. Because histone
H2B is not a substrate for PAD4, we estimate that about 2 citrullines were introduced into
each modifiable core histone. Quantitation of citrullines was performed by colorimetry
(Figure 4-1A). We confirmed histone deimination by Western blot using antibodies that
recognize citrullines at the histone H3 amino terminus (Figure 4-1B). The starting calf
thymus histone preparation had no detectable citrullines (Figure 4-1B, time = 0).
Spontaneously Arising Anti-histone Autoantibodies Bind Non-deiminated Histones
To assess the production of anti-deiminated histones autoantibodies in mice that
spontaneously develop anti-nuclear autoantibodies (ANA), we tested sera from
(NZBxNZW)F1 and their recombinant inbred derivative strain NZM2410 for binding to
non-deiminated histones and deiminated histones. In addition, we tested the contribution
of lupus-predisposing genetic intervals Sle1 and Sle3 that were back-crossed from the
NZM2410 onto the C57BL/6 background (B6.Sle1 and B6.Sle1.Sle3). Sle1 is a locus
that breaks tolerance to chromatin, whereas Sle3 affects functions of myeloid cells (53).
We also tested B6.TC mice, a triple congenic strain that in addition to having the lupuspredisposing genetic intervals Sle1 and Sle3, also carries the Sle2 interval that results in
the spontaneous activation and hyperactivity of B cells. The parental strains, NZB and
NZW, have distinct MHC, H-2d and H-2z respectively. The lupus-predisposing H-2z was
maintained in the NZM2410 mice, whereas the congenics have the H-2b from C57BL/6.
Antibody binding to deiminated histone and non-deiminated histone was assessed by
ELISA (Figure 4-2) and Western blot (Figure 4-3 and Table 4-1). As controls, sera
from age- and sex-matched C57BL/6 mice were used.
By ELISA, (NZBxNZW)F1 (Figure 4-2A), NZM2410 (Figure 4-2B), B6.Sle1
(Figure 4-2C), B6.Sle1.Sle3 (Figure 4-2D) and B6.TC (Figure 4-2E) sera showed
preference for non-deiminated histones over deiminated histones. This preferential
binding was statistically significant for (NZBxNZW)F1, NZM2410, and B6.Sle1.Sle3, as
assessed by a paired, two tailed T-test. The strength of binding differed for different
mice and serum dilutions but binding to non-deiminated histones was equal or greater
than the binding to deiminated histones in all except one B6.TC mouse. We also
confirmed the additive effect of Sle1 and Sle3 loci, as the B6.Sle1.Sle3 combination
resulted in greater absorbance values relative to the B6.Sle1 mice. In parallel assays, sera
from C57BL/6 mice (Figure 4-2F) showed no reactivity to histones. Both deiminated
histones and non-deiminated histones were present in equivalent concentrations on the
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Figure 4-1: In-vitro deimination of histones by PAD4
Calf thymus histones (0.1 mM) were incubated with 0.2 µM PAD4 up to 24 h and
deimination (in nmoles) was measured by colorimetry at 595nm using a citrulline
standard solution. B) Western blot showing deimination of calf thymus histones at
different time points in a 24 h in-vitro PAD4 reaction using anti-deiminated histone H3
antibody.
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Figure 4-2: Binding of IgG from autoimmune prone and control mice to nondeiminated histones and deiminated histones
Sera from (NZBxNZW)F1 (A), NZM2410 (B), B6.Sle1 (C), B6.Sle1.Sle3 (D), B6.TC (E)
and control C57BL/6 mice (F) were tested for IgG binding to non-deiminated histones
(nH) and deiminated histones (dH). Complete binding curves were obtained and OD
values for a single dilution were plotted in panels A to E. We plotted data from 1:1000
dilutions in all other than B where data is from 1:200 dilution. Absorbance values for
each serum corresponding to IgG binding to dH and nH are shown and are connected by
a line indicating the pairs of data for the binding of each serum to the two antigens.
Significance of the readings was tested by paired, two-tailed T-test. Binding to dH was
significantly less than to nH for (NZBxNZW)F1 (p<0.0001), NZM2410 (p=0.031) and
B6.Sle1.Sle3 (p=0.032). The binding of B6.Sle1 IgG (p=0.203) and B6.TC (p=0.278)
tended to be lower to dH. In comparison, control B6 mice showed negligible binding to
either form of histones (F).
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Figure 4-3: Western blot of IgG to deiminated histones and non-deiminated
histones
Equal amounts of deiminated histones (dH) and non-deiminated histones (nH) were
resolved on SDS-PAGE, transferred to nitrocellulose, and stained with Ponceau red
(upper left panel). The stained bands migrating with the mobilities of core and linker
histones are indicated along the margins. Strips of membrane containing nH or dH were
probed with (NZBxNZW)F1, NZM2410, B6.Sle1, B6.Sle1.Sle3 and B6.TC sera at 1:500
dilution and developed with anti-mouse IgG-HRP. Autoimmune prone mice sera bound
nH in preference to dH. The experiments were performed at least three times with
consistent results. One experiment is shown and was used to derive data for Table 4-1.
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Table 4-1:

Summary of Western blot analysis

Histone
Subtype

(NZB X
NZW) F1
(n=7)

NZM2410
(n=8)

B6.Sle1
(n=8)

B6.Sle1.Sle3
(n=8)

TC
(n=7)

Total
(n=38)

H3

7:1

8:4

5:0

8:4

7:0

35 : 9

H2A

2:0

1:0

5:0

6:2

7:0

21 : 2

H4

2:0

4:0

2:0

4:0

6:0

18 : 0

H1

1:0

1:1

2:1

5:4

6:5

15 : 11

Total
12 : 1
14 : 5
14 : 1
23 : 10
26 : 5
89 : 22
Results are listed as a ratio of IgG binding to non-deiminated histones: deiminated
histones. We set 120% of background intensity as threshold for positive bands.
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plates, as seen by the nearly identical binding of the LG2.2 mAb (data not shown) whose
epitope corresponds to first 13 amino acid residues of histone H2B (337).
To examine the preferential binding to non-deiminated histones, we used Western
blotting. The stringency of binding was increased by including both SDS (0.05%) and
NP-40 (0.5%) in the binding buffer. Indeed, under these conditions, many of the sera
bound exclusively or with preference to non-deiminated histones relative to deiminated
histones (Figure 4-3 and Table 4-1). A variety of binding patterns were observed,
including exclusive binding to one or two core histones. Binding to histone H3 was
observed most often, whereas binding to H4 and H2A were rare. In addition, binding to a
band with the mobility of the linker histone H1 was observed in several blots. Overall,
binding was biased toward non-deiminated histones over deiminated histones (Table
4-1), although some IgG binding to deiminated histones was also observed. To assess the
possibility that DNA-anti-DNA complexes present in sera contribute to the observed
histone binding, we treated sera with DNase1 prior to incubation with the histone blots.
None of the sera tested altered their preferential binding to non-deiminated histones
following treatment with DNase1, and the immunoreactivity of DNA-depleted sera was
indistinguishable from untreated sera (data not shown). Therefore, anti-DNA antibodies
did not measurably contribute to the observed results.
(NZBxNZW) F1 Splenocytes Respond to Deiminated Histones or Non-deiminated
Histones
To investigate whether splenocytes from autoimmune (NZBxNZW) F1 mice, are
capable of responding to deiminated histones or non-deiminated histones, we measured
the proliferation of splenocytes from (NZBxNZW)F1 mice of different ages. At 6 to 10
weeks of age, prior to any measurable anti-DNA reactivity, the splenocytes did not
proliferate in response to either form of histone (Figure 4-4A and B). At 20 to 21 weeks
of age, anti DNA autoantibodies could be detected in the sera, and splenocytes
proliferated in response to non-deiminated histones and deiminated histones (Figure
4-4C and D). Thus, splenocyte responses to histones arose in parallel with humoral
responses to DNA. Twenty-five-week-old (NZBxNZW)F1 mice with established
autoimmunity showed splenocyte proliferation in response to deiminated histones and
non-deiminated histones (Figure 4-4E and F), suggesting the presence of histonereactive T cells in the spleens of autoimmune mice. Although some mice showed a
tendency to preferentially respond to deiminated histones, others preferred nondeiminated histones. Notably, preference could switch, depending on the length of
stimulation (Figure 4-4E and F), suggesting that growth characteristics of some
splenocytes may be influenced by deimination. This suggested that T cell help for B cells
with receptors to non-deiminated histones and deiminated histones should be available
following the development of autoimmunity in these mice. Interestingly, splenocytes
from BALB/c mice immunized with deiminated histones proliferated vigorously in
response to deiminated histones yet failed to respond to non-deiminated histones (Figure
4-5). Yet, B cells from BALB/c mice immunized with either non-deiminated histones or
deiminated histones, with or without aTLR7 agonist, showed no response after multiple
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Figure 4-4: Proliferation of splenocytes from (NZBxNZW)F1 mice
Splenocytes derived from (NZBxNZW)F1 mice of different ages were tested for dsDNA
binding by ELISA (A-F). In parallel, splenocytes were stimulated with deiminated
histones (dH) or non-deiminated histones (nH) in vitro, as indicated. Proliferation was
assessed following 20 h, 3 days and 6 days in culture, and the response was determined
by [3H] thymidine incorporation. The results are presented as stimulation indices (SI)
that were calculated from mean cpm values of triplicate wells. The significance of
differences between samples was determined by unpaired T-test and the p values are
indicated.
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Figure 4-5: Proliferation of splenocytes from immunized BALB/c mice
Splenocytes from mice immunized with deiminated histones (A) or non-deiminated
histones (B) were tested for proliferation in response to deiminated histones (dH) or
non-deiminated histones (nH). Two mice were immunized with OVA (C) as control.
The results are presented as stimulation indices (SI) that were calculated from mean cpm
values of triplicate wells incubated with respective antigens for 72 -96 hours. A good
proliferation response to deiminated histones was seen in splenocytes from mice
immunized with deiminated histones, whereas splenocytes from mice immunized with
non-deiminated histones showed low to negligible proliferation.
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immunizations (Figure 4-6).
Spleens of Autoimmune Mice Have Increased Levels of Deiminated Histones
In autoimmunity, the chronic inflammation may be expected to induce PAD4
activation and histone deimination. To test for the presence of deiminated histones in
tissues of autoimmune mice, we dissected tissues from B6.TC mice and littermate
controls. Lysates of bone marrow, spleen, liver and kidney were probed for deiminated
histone H3 and total H3. Out of the 7 B6.TC mice tested, 6 showed detectable amounts
of deiminated histone H3 in their bone marrow and spleen (Figure 4-7A and B, see box).
The spleens of B6.TC mice had markedly increased levels of deiminated histone H3 as
compared to C57BL/6 controls or control cell lysate (Figure 4-7). The overall amounts
of histone H3 were similar in all samples, as indicated by the equivalent
immunoreactivity of an anti-H3 antibody that does not discriminate deiminated histone
H3 from non-deiminated histone H3. Therefore, the bone marrow and spleens of
autoimmune B6.TC mice contained increased quantities of deiminated histone H3. In
addition, the kidneys of one autoimmune mouse exhibited increased levels of deiminated
histone H3 (Figure 4-7C, #12). Unexpectedly, the bone marrow, spleen and kidney of
one C57BL/6 mouse showed elevated levels of deiminated histone H3 (Figure 4-7A, B
and C, #2). Yet, this C57BL/6 mouse showed no binding to either non-deiminated
histones or deiminated histones on ELISA (data not shown).
Discussion
In this study, we observed that in autoimmune mice, B cells readily produce IgG
autoantibodies to non-deiminated histones (Figure 4-2 and 4-3), suggesting the
availability of T cell help. However, autoimmune mice exhibited a striking B cell bias
for non-deiminated histones over deiminated histones. Of all the mice tested by ELISA,
only one B6.TC showed preferential binding to deiminated histones (Figure 4-2E). On
Western blot this serum differed from most others in that it showed equal binding to
deiminated and non-deiminated H1 while the binding to core histones was reduced. In 35
of 35 mice that made anti-histone H3 IgG, preference was invariably in favor of nondeiminated histone H3 (Figure 4-3 and Table 4-1). In 19 animals, we failed to detect
antibodies to deiminated histones by immunoblotting, whereas antibodies to nondeiminated histones were readily observed (Figure 4-3). Strongly biased binding to nondeiminated histones indicates that autoantibody epitopes often (or exclusively) depend on
arginines that are substrates for PAD4. This is surprising, as other, non-arginine
containing epitopes should also be accessible for antibody binding. These results indicate
that, even in overt autoimmunity, IgG binding to deiminated histones is suppressed, and
autoantibody binding is focused on arginine-containing epitopes that are absent from
deiminated histones. Deimination itself is unlikely to interfere with antibody binding to
deiminated histones because autoantibodies to deiminated histones are prevalent in
patients with Felty’s syndrome (303). One possible explanation for binding to nondeiminated histone epitopes in preference over deiminated histones is that deiminated
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Figure 4-6: B cell response after 3rd immunization using Imiquimod, a TLR-7
agonist as adjuvant
Sera from pre-immunized mice (A, D, G) as well as sera after the third immunization
with imiquimod (C, F, I) or without (B, E, H) were tested against the antigens in the
legend. Reactivity to antigens was unchanged before and after immunization in mice
immunized with deiminated histones (A and B) and non-deiminated histones (D and E).
With imiquimod as adjuvant, the response to deiminated histones or non-deiminated
histones was not enhanced, but the binding to poly-L-lysine increased (C and F). The
response of ovalbumin (OVA) immunized mice to OVA increased after immunization, as
expected (H and I).
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Figure 4-7: Western blot detection of deiminated histones H3 in mouse tissues
Equal amounts of freshly prepared lysates from bone marrow (A), spleen (B), kidney (C)
and liver (D) of autoimmune B6.TC and control C57BL/6 mice were blotted onto
nitrocellulose membranes and probed with anti-deiminated histone H3 (dH3) antibody.
A total of 12 mice were analyzed in two separate blots and same tissues are grouped
together for presentation. Lanes corresponding to B6.TC tissues are highlighted in box.
As control Jurkat lymphoma cells were used (B). The same blots were also re-probed
with an antibody that recognizes total histone H3 (Pan H3) to confirm equal loading of
lysates. Bone marrow and spleen of 6 out of 7 B6.TC mice showed presence of
deiminated histone H3.
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histones remain effective tolerogens even after development of autoimmunity.The
striking bias toward non-deiminated histones binding was particularly evident in animals
containing the lupus susceptibility locus Sle3 (Figures 4-2 and 4-3). As established by
Mehrad et al. (53), neutrophils from Sle3 congenics respond more vigorously to bacterial
infection and release MPO by degranulation. In response to bacteria or other
inflammatory stimuli, neutrophils release deiminated chromatin from the cell to the
extracellular milieu (202, 203). Deimination indeed may be required for chromatin
decondensation that accompanies extracellular chromatin release (213). It has been
argued that microbes become entangled in this released chromatin and that they are killed
by MPO and other bactericidal enzymes that associate with the chromatin (201).
Therefore, this chromatin may act as a neutrophil extracellular trap (NET) that serves to
contain and destroy microbial pathogens (194). These findings suggest that NETs are
important adaptations of innate immunity and that NETosis represents a specific form of
programmed cell death that is morphologically, mechanistically and functionally distinct
from apoptosis (196). The data of Mehrad et al. (53) suggest that genes in the genetic
interval of Sle3 favor neutrophil activation and subsequent NET chromatin release.
To test the hypothesis that deiminated histones act as tolerogens in autoimmune
mice, we prepared lysates from tissues of B6.TC and control mice and analyzed them for
deiminated histone H3. Spleens and to a lesser degree the bone marrow from 7-mo-old
female B6.TC mice generally exhibited elevated levels of deiminated histone H3. The
kidney from these mice, as well as tissues from control mice, had reduced or background
levels of deiminated histone H3 (Figure 4-6). Interestingly, kidney lysates from one of
the autoimmune mice showed elevated levels of deiminated histones, although it is not
known whether the increase in deiminated histones was correlated with any aspect of the
pathogenic process in this mouse.
Our observations suggest a tolerance mechanism that may operate in the spleens
of autoimmune mice. Autoimmune mice may generate a chronic inflammatory milieu in
which neutrophils are more likely to become activated. In these mice, neutrophils may
induce histone deimination and become sequestered in the spleen. The clearance of
activated neutrophils through the splenic reticuloendothelium is consistent with the
observed migration of neutrophils to the light zone in the spleen of LPS-treated mice
(338). Detection of deiminated histone H3 in the spleens of autoimmune mice is
consistent with the release of NETs (202). Should chromatin containing deiminated
histones be externalized in the spleen, serum nucleases such as DNase1 may degrade it
into separate nucleosomes. The effect of the solubilized nucleosomes may be to tolerize
splenic B cells that express receptors for anti-deiminated histone epitopes. The only antihistone reactive B cells escaping this tolerogen would be those that bind non-deiminated
histones epitopes, as was observed in our study.
Induction of splenic tolerance by soluble antigen is consistent with earlier studies
demonstrating the induction of tolerance in germinal center B cells (339, 340). Mice
harboring anti-hen-egg-lysozyme B cells respond to an injection of soluble antigen by
rapid apoptosis of centrocytes (340). The presence of deiminated histones in the spleens
of autoimmune mice together with the B cell response targeting non-deiminated histones
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suggests that deiminated histones act as effective tolerogens in the spleens of
autoimmune mice. If so, the ability of soluble nucleosomes to establish tolerance may be
beneficial in immune responses to microbial infections. Because NET-ted microbes may
be engulfed by antigen presenting cells, it may be vital for the organism to respond to
bacteria that become entangled in NETs, while repressing a response to NET/chromatin
Ags. Therefore, it is meaningful to predict that NETs act as signals to enhance the
immune response to infections, and that effective tolerance mechanisms exist to prevent
“collateral” responses to NET chromatin. If peripheral tolerance to deiminated histones
is preserved in autoimmune mice, our results may suggest ways to re-establish tolerance
in overt autoimmunity.
Conclusion
Autoimmune disorders are associated with ongoing inflammation. Our results
show that autoantibodies from lupus prone mice preferentially recognize non-deiminated
histones over deiminated histones. Consistent with inflammatory stimuli causing histone
deimination in neutrophils, we found high levels of deiminated histone H3 in bone
marrow and spleen of lupus prone mice. We conclude that the biased autoantibody
response to non-deiminated histones seen in lupus mice, in spite of the availability of
deiminated histones antigen indicates effective tolerance against deiminated histones.
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CHAPTER 5.

DISCUSSION

Despite decades of intense research, we do not know the stimuli that trigger the
production of autoantibodies in systemic autoimmune diseases (341). The autoantibodies
themselves have been studied and found to be useful as diagnostics for different
autoimmune diseases. For example, autoantibodies reacting against nuclear antigens,
most notably DNA and histones, are a distinguishing feature of systemic lupus
erythematosus (SLE), whereas autoantibodies to a citrullinated cyclic peptide (CCP) are a
reliable diagnostic for rheumatoid arthritis (RA). A plausible prediction is that the
careful analysis of autoantibodies will lead to a better understanding of their origins.
The structure of autoantibodies argues that they are selected for improved binding
to autoantigens. The genetic mechanisms that give rise to autoantibodies argue strongly
in favor of this conclusion. Autoantibody sequences indicate that even though diverse V
genes code for anti-DNA and rheumatoid factor (RF) autoantibodies in murine models of
SLE and RA, junctional diversity and somatic mutations make essential contributions to
binding (342-344). In consequence, only few B cell clones secure conditions for
expansion. The expanded autoreactive B cell clones participate in antigen presentation,
given that T cell help promotes antibody H chain isotype switching and selects for
mutations that improve antibody binding to autoantigens. As result, autoantibodies
acquire all of the molecular hallmarks of affinity maturation, just as antibodies to foreign
antigens do (345). Therefore, the identification of molecular features of autoantigens that
drive systemic autoimmune diseases holds the key for understanding the pathways that
stimulate the production of autoantibodies.
Post-Translational Modification of Autoantigens
Autoantibodies frequently target post translational modifications (PTM) in selfantigens (64, 65), including PTM that are introduced during apoptotic cell death (346,
347). Thus, PTMs may provide a mechanism for converting innocuous self components
into targets of an autoimmune response. PTMs generate “neo- epitopes” that alter
antigen processing and presentation (348). One such PTM is the enzymatic conversion of
arginines in a polypeptide chain to citrullines. Citrullination, also called deimination, is
the work of peptidylarginine deiminases (PADs). PADs are Ca++-dependent enzymes
that are conserved in all vertebrates (204, 205). The conserved nature of PADs implies
an important physiological role. Indeed, citrullination regulates zygotic development, the
myelination of neurons, and properties of the epidermis.
PAD4 is the only PAD that has a nuclear localization signal and deiminates
histones H2A, H3, and H4 (268, 327). A link exists between PAD4 haplotypes and risk
of RA. Alleles linked to an increased susceptibility to RA encode a more stable PAD4
mRNA than alleles that are neutral for RA (228). The increased mRNA stability may
lead to increased expression of PAD4 in individuals bearing the susceptible haplotype.
An association between deiminated proteins and autoimmune diseases strongly suggests
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that deimination generates novel epitopes that are able to break tolerance and initiate
autoimmune responses.
PAD4 Action in Neutrophils
PAD4 is most abundantly expressed in granulocytes (349), monocytes (350) and
mast cells (310). PAD4 may associate with cytoplasmic granules, but it also enters the
nucleus where it may participate in gene regulation by deiminating histones (268).
Deimination transforms a positively charged amino acid (arginine) into a neutral amino
acid (citrulline), resulting in the net loss of one positive charge per modified residue
(206). Therefore, deimination changes not only the primary sequence of a protein but
also its net charge. During the reaction, the guanidino group of arginine is attacked by a
Cys residue of PAD4, resulting in the formation of a tetrahedral adduct (351). A
nucleophilic attack by a water molecule then cleaves the adduct to form the keto group of
citrulline, while releasing ammonia and regenerating the Cys residue of the enzyme (206,
207). The net result is the conversion of arginine to citrulline with a mass shift of +1 Da.
The activation of PAD4 in neutrophils is exquisitely sensitive to inflammatory
stimuli, such as f-MLP, LTA or LPS (202). In contrast, the induction of neutrophil
apoptosis blocks PAD4 activation (202). Whereas senescent neutrophils that were not
needed to fight an infection die by apoptosis (352, 353), neutrophils faced with
microorganisms in the course of an infection perform an elaborate form of cell suicide.
Those neutrophils die by ejecting nuclear chromatin in order to capture, or “trap”,
microbial pathogens (194). PAD4 activity precedes and facilitates the release of
chromatin from neutrophils (203). In fact, PAD4 is essential for neutrophil extracellular
trap (NET) release and, in the absence of PAD4, the innate response to bacterial
infections is impaired (213). Since the discovery that neutrophils release chromatin in an
innate response to infections (194), NET release has been reported in responses to
bacterial and fungal infections. NET release is triggered by neutrophil encounter with
Staphylococcus aureus (194) or Mycobacterium tuberculosis (354) and in response to
exposure to Candida albicans (195) and Aspergillus fumigatus (355, 356). NETs
function in trapping and damaging microorganisms and this explains how extracellular
nucleases produced by bacteria function as virulence factors (309). The release of NETs
is linked to various clinical complications of infectious diseases, including bacterial
sepsis (357, 358) and the increased risk of thrombosis (196). Interestingly, more serious
infections and blood clots are known as complications in a number of autoimmune
disorders (359). These complications could be linked, in part, to the inopportune release
of NETs from autoimmune patient neutrophils.
Clearly, NETs deserve wider experimental scrutiny because, in infections (285),
or in response to adjuvants (312), NETs connect citrullinated histones with strong
immune stimuli. This feature of NETs could be instrumental in breaking tolerance and
inducing an autoimmune response to chromatin antigens.
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Neutrophil Extracellular Traps and Autoimmunity
That NETs may stimulate autoimmunity follows from discoveries that
autoantibodies target various NET components. Autoantibodies from patients with
systemic autoimmunity may recognize innate immune defense proteins that associate
with NETs. This is the case for the major NET components, including the granule
proteases elastase, cathepsin G and proteinase 3 (235, 236, 238), as well as for various
bactericidal peptides that are stored in granules and co-purify with NETs, such as
neutrophil defensins and the LL37 peptide (239, 240). Separate studies indicate an
increased abundance of activated neutrophils and increased serum levels of neutrophil
granule contents in patients with more advanced disease (235, 287). In addition, the
severity of lupus may also correlate with the levels of autoantibodies to NET components
(243). Thus, lupus autoantibodies target NET-associated proteins in addition to the
NETs’ structural scaffold, DNA and histones.
Other studies directly point to neutrophil activation as a key factor in the
stimulation of autoantibodies. Notably, SLE patients possess neutrophils that are prone
to NET release (241). The exacerbated response of neutrophils to lupus autoantibody
complexes was discovered in studies that used cells from juvenile lupus patients (241).
In turn, NETs may persist for a longer time in autoimmunity, as SLE patients’ anti-DNA
antibodies protect NETs from degradation by nucleases (243). Together, these findings
suggest that, in SLE, the release of NETs may be more easily triggered by stimuli, NETs
may induce the production of anti-NET antibodies, and the NET antigens may persist in
tissues because they are protected by autoantibodies. Thus, NET antigens and anti-NET
autoantibodies may be linked in a pernicious pathogenic cycle.
Autoantibodies to Deiminated Histones
To initiate our search for autoantibodies to deiminated histones, we collected sera
from patients with SLE and RA. In addition, we obtained sera from patients with Felty’s
syndrome (FS), a disorder that shares features of SLE and RA and is defined by the triad
of severe arthritis, splenomegaly and neutropenia. FS arises in 1-3% of RA patients after
an extended period of incompletely mitigated disease (254, 360). FS patients experience
severe destructive arthritis and develop extra-articular manifestations including rheumatic
nodules and vasculitis (361). Neutropenia is thought to be associated with an intense and
ongoing autoimmune reponse to neutrophil surface antigens.
Experiments suggest that neutropenia in FS follows from autoimmune etiology
rather than a production defect. In mice infused with the sera or isolated immune
complexes of FS patients, neutrophil counts drop precipitously, suggesting autoimmunity
as the mechanism (362). Both immune complexes and soluble antibodies from FS
patients bind neutrophils and mediate their sequestration in the spleen (363). The spleen
of FS patients exhibits an expansion of red pulp, sinus hyperplasia, macrophage
infiltration, and prominent germinal centers (364). These hallmarks of increased splenic
activity indicate that clearance of activated neutrophils by the spleen may promote FS.
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Interruption of the self-sustaining autoreactivity by removal of the patient’s spleen
restores neutrophil counts, arguing that the spleen provides a sink for neutrophils in FS
(364). Thus, it is reasonable to argue that autoantibodies against neutrophil antigens in
FS drive neutropenia by splenic sequestration of neutrophils. To understand FS, it will be
important to identify the neutrophil targets of autoantibodies.
There are three observations that suggest histone deimination during neutrophil
activation as a possible pathogenic mechanism in FS. First, FS patients score positive for
binding to the cyclic citrullinated peptide, a screening test that identifies 77% of FS
patients (365, 366). Second, a remarkably high percentage of FS patients have
autoantibodies to histones, and reports indicate that over 80% of FS sera contain antihistone IgG (246). Third, there is sequestration of activated neutrophils in the spleen that
may, over time, induce autoantibody production against neutrophil antigens. Because we
hypothesized that stimulation of neutrophils in FS would lead to PAD4 activation and
histone deimination, and because FS patients make anti-histone antibodies, we decided to
test FS patient sera for IgG to deiminated histones.
To test for the presence of antibodies to deiminated histones, we reacted histones
from calf thymus with recombinant PAD4 to completion. To compare sera from different
autoimmune disorders (FS, RA and SLE), tests were performed at equal IgG
concentrations. ELISA for deiminated and non-deiminated histones revealed that
majority of FS sera contained IgGs that bound deiminated histones with preference over
non-deiminated histones. In contrast, all 37 RA sera, except 2, showed nearly equal
binding to deiminated and non-deiminated histones. Using Western blots, we probed the
binding of antibodies to individual histones. Deiminated H3 was the major target
autoantigen, although binding to other core histones was also observed. In some cases,
IgG preferentially bound non-deiminated H2A, H4 and linker histone H1.
Overall, ELISA and Western blot results were in agreement, although some serum
samples showed preferred binding to deiminated histones by only one of the methods.
The difference arose because of strong binding of antibodies to both antigens on Western
blot was recorded as preferential binding by ELISA. In addition, multiple reactivities
could be distinguished by Western blot that could cancel each other by ELISA (e.g.
antibodies against deiminated H3 and non-deiminated H4). In one case, an SLE serum
showed remarkable preference for deiminated linker histone H1 by Western blot, yet
ELISA showed no preferential binding because H1 was only a minor component of the
calf thymus core histone preparation used in coating the plates. Western blots also
detected slight preference for deiminated H3 in several RA samples. We concluded that
this weak binding was due to cross-reactivity between antibodies to CCP and citrulline
residues on deiminated H3 (367).
The difference between FS and RA samples is remarkable and argues that
neutropenia in FS may be activation-induced neutropenia. Neutropenia is also a known
complication of SLE [85], suggesting why some SLE sera showed preference for
deiminated histones. Autoantibodies to deiminated histones, an antigen that is produced
during neutrophil activation represents strong evidence that NETs contribute to
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autoimmunity in FS. As neutrophils are involved in responses to infections, our findings
suggest a novel path whereby sustained infection may lead to autoimmunity. Neutrophil
activation and NET formation are also induced by inflammatory cytokines, suggesting
how one might arrive at a positive feedback loop that is the hallmark of autoimmune
disorders.
Lupus Mice Do Not Make Antibodies to Deiminated Histones
As (NZB X NZW)F1 mice make anti-chromatin autoantibodies and have higher
levels of Type 1 IFN (368) that predispose for NET formation (241), we tested sera from
(NZB X NZW)F1 mice and the recombinant inbred New Zealand Mixed NZM2410
strain for the presence of anti-deiminated histone antibodies. We also tested sera from 3
congenic strains that were derived by backcrossing lupus predisposing genetic intervals
of NZM2410 mice on a B6 background (369). Studies have shown that the Sle1 genetic
interval promotes production of anti-chromatin antibodies (49, 50) while the Sle2 interval
is responsible for a defect in B cells and renders them hyperactive (51). The Sle3 genetic
interval results in hyperactivation of myeloid cells (53). Neutrophils from B6 mice
harboring the Sle3 interval respond vigorously to bacteria by degranulation (53). We
intended to establish if these autoimmune mice make autoantibodies to deiminated
histones by screening sera from these autoimmune mice for reactivity to deiminated
histones. The comparison between different mouse sera also could reveal which genetic
element, if any, contributes in autoimmune response against deiminated histones. Both
ELISA and Western blot demonstrated that spontaneously arising autoantibodies in the
autoimmune mice we tested recognize non-deiminated histones over deiminated histones.
The preference for non-deiminated histones became more evident on Western blot where
almost all the mouse sera bound histones with preference over non-deiminated histones.
In 24 out of 35 sera no binding to deiminated histones could be detected, whereas
antibodies to non-deiminated histones were easily observed. This argues that B cell
responses in autoimmune mice are preferentially targeted against epitopes that contain
arginines. For the majority of these sera, deimination of arginine to citrulline reduced
binding to histones.
Splenocytes of Autoimmune Mice Respond to Both Deiminated and Non-deiminated
Histones
Splenocytes from (NZB X NZW)F1 autoimmune mice of an age when
autoimmunity manifested as indicated by the emergence of anti-dsDNA antibodies
proliferated in response to deiminated and non-deiminated histones. Splenocyte
proliferation in individual mice was biased to either non-deiminated or deiminated
histones indicating that deimination of arginine to citrulline affects recognition of
proteins by splenocytes. In individual mice, the proliferation was stimulated more by
non-deiminated histones but in some the response later switched to deiminated histones.
This suggests that the growth characteristics of some splenocytes may be influenced by
deimination. Possibilities for a biased response to deiminated vs. non-deiminated
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histones may include differences in processing and presentation of the two antigens.
Proteolytic processing of proteins is a prerequisite for MHC loading. Though many
proteases of the lysosomal compartment have overlapping activity, certain proteases are
specific for digesting and presenting specific proteins. For example, tetanus toxin C
fragment (TTCF) is specifically cleaved by asparaginyl endopeptidase (248).
Consequently, APCs treated with inhibitors of asparaginyl endopeptidase, and not other
protease inhibitors, have reduced presentation of TTCF antigen (248). With regard to
deiminated histones, cleavage by neutrophil proteases may shift position relative to nondeiminated histones. Neutrophils express cathepsin H (249), a lysosomal cysteine
proteinase involed in antigen presentation (250). Cathepsin H recognizes arginine as its
major cleavage site. Neutrophils also express trypsin, a protease that cleaves proteins at
carboxy terminal of arginine. Thus, by deiminating arginine to citrulline, the loss of a
cleavage site on histones may result in different peptide fragments. Differences in
presentation may influence T cell central tolerance and B or T cell activation in the
periphery. As splenocytes from (NZB X NZW) F1 mice proliferated in response to both
deiminated and non-deiminated histones, we suggest that MHC presentation of
deiminated histones is intact in lupus prone autoimmune mice.
The paucity of antibodies to deiminated histones despite the presence of
splenocytes that respond to deiminated histones suggests that B cells are tolerant of
deiminated histones even in autoimmune mice. Theoretically, the B cell repertoire is
very large. It is estimated that B cells can make receptors of more than 1011 specificities
(370). Thus it is highly likely that B cells from (NZB X NZW) F1, NZM2410 and
congenic autoimmune mice have B cells that can recognize histone epitopes with
citrullines. The fact that such B cells either fail to develop or are not activated by
deiminated histone antigens, or fail to respond even in an inflammatory environment
where autoantibodies to non-deiminated histones are readily produced, argues for B cell
tolerance to deiminated histones.
B cell tolerance to self-antigens is induced either during development or in the
periphery (371). During development, B cells that express self-reactive BCRs undergo
receptor editing which has an increased likelihood of a change in affinity of binding to
self-antigens (372, 373). B cells that still express a self-reactive BCR are deleted from
the repertoire, although notable exceptions have been observed (374). As result of
tolerance, a majority of self-reactive B cells can be prevented from populating the
periphery. Some self-reactive B cells that escape to periphery are kept in a state of nonresponsiveness or anergy. Essentially contact with self-antigens in absence of
engagement by helper T cell or TLR ligands results in B cell anergy (375).
Presence of Deiminated Histones in Lymphoid Organs of Autoimmune Mice
In search of putative tolerogens, we probed tissue lysates from primary and
secondary lymphoid organs of B6.TC congenic with an antibody to deiminated H3 and
compared the results with control C57BL/6 mice. We found that both bone marrow and
spleen of B6.TC mice have higher levels of deiminated H3 than the controls. This
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suggests that B cell tolerance to deiminated histones may be maintained by presence of
deiminated histones both at developmental stages and in the periphery. Since we have
used whole tissue lysates for our analysis, we do not know the cellular source of
deiminated histones or how they are presented to B cells. Overall, our results indicate
that high levels of deiminated histones in autoimmune mice negatively influence B cell
responses to deiminated histones. How deiminated histones induce tolerance or what
precise mechanisms are involved in tolerance to deiminated histones need further
investigation.
B and T Cell Responses in BALB/c Mice Immunized with Deiminated Histones
Immunization with deiminated fibrinogen in DR4-IE transgenic mice was able to
induce arthritis characterized by synovial hyperplasia and ankylosis (376). BALB/c mice
immunized with deiminated fibrinogen in presence of Freund's complete adjuvant
produced an antibody response to deiminated fibrinogen but not to non-deiminated
fibrinogen (377). By immunizing BALB/c mice with deiminated histones in the presence
of different adjuvants, we tested whether deimination itself is sufficient in inducing
antibody responses against histones. Immunization with both deiminated and nondeiminated histones failed to induce antibodies to histones even after multiple
immunizations. That either form of histones failed to induce any B cell response in the
presence of adjuvants like LPS or Imiquimod, a TLR7 agonist, suggest active tolerance to
histones with or without deimination.
The splenocytes of BALB/c mice immunized with non-deiminated histones when
incubated with either form of histones showed poor proliferation response similar to that
observed with media alone. The splenocytes from mice immunized with deiminated
histones showed increased proliferation in response to both deiminated and nondeiminated histones. Previously Hill et al have found that deiminated peptides are
presented better by MHC molecules of DR4-IE transgenic mice (224). Similarly, we
found increased proliferation response in presence of deiminated histones suggesting that
deimination influences antigen processing and presentation to T cells. The fact that mice
immunized with deiminated histones, in spite of having splenocytes that may respond to
deiminated histones, still showed no B cell response to histones indicate strong B cell
tolerance to histones that is not affected by deimination.
Deiminated Linker Histones in Neutrophils
Linker histones bind linker DNA at entry and exit points of nucleosomes, thus
condensing chromatin into a compact structure (378-380). H1 has multiple isoforms all
of which have similar structural features; they are composed of a central globular domain
flanked by a long lysine rich C-terminal domain tail and a short N-terminal region (381).
PTMs, particularly phosphorylation on the C-terminal tail of H1 during different stages
of cell cycles are important for chromatin remodeling (382). The globular domain of H1
also binds chromatin and is involved in protecting it from nuclease digestion (383, 384).
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Specific interactions of this domain with nucleosomes may influence the structural
geometry of chromatin as well as gene expression (385-387). The globular domain of H1
contains positively charged residues that interact with nucleosomes through two distinct
binding sites. Strong contribution to binding at the first site in histone H1.0 comes from
residues: His 25, Arg 47, Lys 69, Lys 73, Arg 74 and Lys 85, whereas for second smaller
site contribution to binding was by Arg 42, Arg 94 and Lys 97 (318). In all these
positions introduction of a negative charge by replacement of one of these residues with
glutamic acid reduced binding, while introduction of residues with a positive charge
resulted in near similar or higher binding (318). All somatic subtypes of H1 have
arginine residues in or near the DNA binding region of globular domain (297). With
conversion of positively charged arginine to neutral citrulline deimination results in a net
loss of charge that may affect its interactions with linker DNA. Formation of NETs
during neutrophil activation requires rapid changes in chromatin structure. Deimination
of histones is considered essential for release of NETs as neutrophils deficient in PAD4
are also deficient in making NETs (203). That the primary function of linker histones is
to keep chromatin condensed, that deimination is essential for NET release, and that
deimination may alter interaction between H1 and DNA, prompted us to investigate if
linker histones in neutrophils are deiminated.
By extracting total RNA from circulating neutrophils we assessed mRNA
expression for different H1 subtypes on a microarray chip. Among the different subtypes
H1.4 was highly expressed in neutrophils and its expression levels were about 4-5 fold
more than H1.0 that has the second highest expression levels. The expression levels for
H1.1, H1.3 and H1.5 were low and below the housekeeping gene HGPRT used as control
whereas H1.2 was expressed at intermediate levels between HGPRT and H1.0. We
chemically extracted H1 from neutrophils treated with ionophore in presence of Ca++
and found deimination of H1 both by probing it with Anti-Cit (modified) Ab by Western
blot and also by Q-TOF Mass Spectrometery followed by MSMS where we identified
peptides with characteristic +1 Da mass shift of arginine converting to citrulline. We
identified deiminated peptides that are unique to H1.0 and H1.5 or shared between H1.2,
H1.3 and H1.4. We also identified peptides with unique sequences corresponding to
H1.0, H1.2, H1.4 and H1.5 indicating the presence of these H1 subtypes in neutrophils.
With these results we identified linker histone H1 as a substrate for deimination. How
deimination of H1 affects its interaction with DNA and what role, if any, deimination of
H1 plays in NET formation will require further studies.
Autoantibodies to Deiminated Linker Histones
As antibodies to H1 are present in large number of SLE patients, we tested SLE
sera for the presence of anti-deiminated histone H1 antibodies by using in-vitro
deiminated recombinant H1.2. Only 2 of 24 SLE samples showed preferential binding to
deiminated histone H1.2 over non-deiminated H1.2 with Western blot. One of the SLE
serum sample, SLE6, showed more than 8 times preference for deiminated H1.2 over
non-deiminated H1.2 by Western blot and we further used this serum to characterize
autoepitope on H1.2. Two synthetic 16mer peptides containing citrulline in the position
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R32 and R53 of H1.2 were prepared for competition with deiminated H1.2 to binding to
SLE6 autoantibodies in Western blot. The assay showed that the peptide R53Cit
competes more effectively for binding to deiminated H1.2 than R32Cit, indicating that
deimination of Arg53 occurs within the SLE6 epitope. Arg53 of H1.2 shows sequence
homology with Arg42 of H1.0, which is known to be a DNA binding residue. Mutation
of Arg42 to glutamic acid on H1.0 which shares sequence homology with Arg 53 of
H1.2, decreased DNA binding (318). A similar effect can be deduced for its conversion
to citrulline that is also neutral in charge.
We also tested serum samples from 20 patients each of Sjogren’s syndrome,
Scleroderma, and RA for presence of anti-deiminated H1 antibodies. We also included
samples from FS patients that have earlier showed some preferential binding to
deiminated calf thymus H1 in our survey. The FS sera showed slight preference to
deiminated H1.2 over non-deiminated H1.2 (binding ratio of deiminated histones/nondeiminated histones: 1.2-1.3) but this was much less than expected from the Western blot
using calf thymus histones. This may be due to the fact that antibodies are reacting more
to calf thymus histones recognize a H1 subtype other than H1.2 or perhaps different
adjoining sequences of calf thymus and human H1.2 are responsible for difference in
binding. While testing other autoimmune disorders for the presence of anti-deiminated
histone antibodies we found only 1 out of 20 Sjogren’s syndrome patients’ samples that
showed preferential binding of autoantibodies to deiminated H1.2. Rest of the Sjogren’s
syndrome samples and also the samples from Scleroderma and RA patients did not
discriminate between binding to deiminated and non-deiminated histone H1.2. We
conclude from our screening that antibodies to deiminated histone H1 occur rarely in
systemic autoimmune disorders.
Inferences from Human and Mice Antibody Response to Deiminated Histones
Deimination of histones in neutrophils occurs in response to inflammatory stimuli
(202) and consistent with this we found elevated levels of deiminated histones in
circulating neutrophils of RA patients as compared to controls. Increased neutrophil
activation is also reported in SLE patients where increased levels of Type 1 IFN prime
neutrophils to make NETs (240, 241). Increased levels of neutrophil NETs in SLE
patients are associated with release of immunostimulatory self-peptides and nuclear
autoantigens (242). When sera from patients with RA, SLE and FS patients were tested,
we found that the majority of FS patients have antibodies to deiminated histones, whereas
only a small minority of patients in RA and SLE make anti-deiminated histone
antibodies. Both RA and SLE patient sera bound histones on ELISA and Western blot
but their binding was not much affected by histone deimination. This implies that
deiminated residues do not affect the binding of a majority of RA and SLE anti-histone
autoantibodies. The preference for deiminated histones by autoantibodies in FS, a
disorder characterized by destruction and sequestration of neutrophils in the spleen (364),
suggests that deiminated histones released from neutrophils may be involved in the
autoimmune process of FS. Although, the majority of RA sera recognize deiminated
antigens, in our assay only a few sera showed higher binding to deiminated histones. The
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facts that FS occurs in patients who have long standing RA, that anti-deiminated histone
antibodies are found in majority of FS rather than RA patients and that antibodies to other
deiminated proteins arise early in RA patients, suggest that while deimination enhances
immune reactivity to many proteins, a response to deiminated histones is not easily
induced.
Our results from the study of various lupus prone and control mice support the
idea of strong tolerance to deiminated histones. On screening sera from lupus prone mice
that readily make autoantibodies against chromatin including histones, we found that
autoantibodies in these mice have much higher preference to non-deiminated histones
than deiminated histones. We found increased levels of deiminated histones in bone
marrow and spleen of autoimmune B6.TC mice which come presumably from
neutrophils activated with higher Type 1 IFN levels (241, 368) together with ongoing
autoimmune injury seen in these mice. Although the exact mechanisms of tolerance to
deiminated histones are unknown, the fact that we found antibodies to deiminated
histones only in FS, a severe variant of arthritis occurring in patients with long standing
RA, suggests that unusual circumstances are needed to elicit such autoantibodies. The
inability of BALB/c mice to make antibodies to deiminated histones when immunized
with excess of deiminated histones suggests that this is indeed the case. There can be
serious consequences for health in case tolerance of deiminated histones is compromised,
a component of NETs released during innate neutrophil response to infections (194, 285).
This is evident in case of FS where we found antibodies to deiminated histones and
which differs from RA in having severe arthritis, extra-articular manifestations and a high
susceptibility to infections due to lower neutrophil counts.
Model of Autoimmune Pathogenesis in Felty’s Syndrome
We propose the following model of FS pathogenesis based on the biological
properties of neutrophils, our data on the high incidence of autoantibodies to deiminated
histones, and the disease progression in FS (Figure 5-1). The diagram connects the
clinical observations that characterize FS, for example the pre-existing arthritis,
neutropenia, splenomegaly and an increased incidence of infections, with the neutrophil
response to infections and inflammation. In these circumstances, neutrophils induce
histone deimination and expel chromatin from the cell. NETs containing deiminated
histones, in complex with bacterial adjuvants, are the most likely antigenic trigger to
account for the production of autoantibodies to the modified histones. These
autoantibodies, similar to other ANCA, may further stimulate neutrophils, thus
completing a cycle that is self-sustaining and drives depletion of mature neutrophils.
Clearly, our model is simplified and incomplete, as our data from other autoimmune
disorders imply. Even though SLE patients may exhibit increased neutrophil activation
and neutropenia, we failed to detect a high incidence of antibodies to deiminated
histones. Thus, one might suspect that tolerance mechanisms prevent the development of
autoantibodies to deiminated histones and only sustained immune stimulation breaks this
tolerance. What factors break tolerance to deiminated histones in FS remains to be
determined. Nevertheless, the increased severity of FS as compared to RA, with its
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Figure 5-1: A model of autoimmune pathogenesis in Felty’s syndrome
Diagram shows proposed relationships between clinical manifestations and disease
mechanisms. For details, see text.
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rapidly progressing arthritis, extra-articular manifestations and life threatening
neutropenia, clearly indicate the need to identify the pathogenic mechanisms of FS.
Future Directions
An increased expression of PAD4 mRNA is observed in RA patients and they
have increased titers of anti-CCP antibodies. Our results that antibodies to deiminated
histones are predominantly present in FS patients, a severe variant of RA with
splenomegaly and neutropenia; and only infrequently in RA and SLE patients highlight
how autoimmunity against deiminated histones contributes to progression of RA to a
more severe and crippling form. Anti-deiminated histone antibodies are the first in the
group of known ACPAs where the process of deiminated antigen release can be assumed
to be activated neutrophils (202). Further research needs to be done to better understand
the relationship between neutrophils, PAD4 and autoimmunity. A detailed study is
needed to understand how and when these antibodies arise; and how they contribute to
disease manifestations. Many studies have found ACPA to be associated with increased
severe arthritis in RA. As FS mostly occurs in patients with long standing RA (254,
360), further studies aiming to correlate the emergence of anti-deiminated histones
antibodies with onset, duration and progression of FS in RA patients will help to
understand autoimmune responses against this deiminated antigen.
Certain MHC haplotypes such as HLA-DRB1*04 associate with ACPA positive
RA (388) and studies have shown that deiminated pepties preferentially bind such MHC
molecules (224). Research into FS MHC haplotypes associated with anti-deiminated
histone antibody response will provide further insights into the development of
autoimmunity to deiminated histones. If an association exists between the development
of anti-deiminated histone antibodies and particular MHC haplotypes, then it might be a
good screening test for identifying RA patients at risk for developing FS. A standardized
anti-deiminated histone IgG ELISA may be developed to monitor such patients and RA
patients making anti-deiminated histone antibodies might be ideal candidates to for
therapeutic intervention with PAD4 inhibitors.
Clinically related to FS is LGL leukemia, in which patients suffer from
neutropenia and arthritis similar to, seen in FS (389, 390). Such similarities have led
many to believe that FS and LGL belong to the same spectrum of diseases and share
common pathological mechanism (255, 390, 391). Because we found that antideiminated histone antibodies are predominantly present in FS patients, we propose that
screening LGL patients for these antibodies will be a good way to test whether etiology
of LGL is as similar to FS as its clinical features. A key difference between LGL and FS
is in the mechanism of neutropenia. In LGL neutropenia is supposed to occur due to
production defect as bone marrow become infiltrated by leukemic lymphocytes (392,
393) that outcompete myeloid cell precursors or induce apoptosis during development
(394). On the contrary neutropenia in FS is due to sequestration of mature activated
neutrophils in the spleen (363, 364, 395). As deimination of histones in neutrophils is
seen on activation, we hypothesize that anti-deiminated histone antibodies will be present
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in FS but not in LGL patients. Thus, simple ELISA and Western blot for the presence of
these antibodies in LGL patient sera will provide useful information to discriminate
between these two disorders.
Another important area of potential research is to investigate and understand the
role deimination of histone plays in neutrophil biology. So far the only role suggested for
histone deimination is in facilitating neutrophil NETs (203). Yet the mechanism how
deimination plays a role in unraveling chromatin is not understood well. With conversion
of positively charged arginine to neutral citrulline there is a possibility of decreased
interaction between DNA and histones. Careful characterization of interactions between
DNA and histones is needed to understand whether this mechanism is involved in the
release of NETs. We have also identified that linker histones, responsible to maintain
compact chromatin structures in cells, are substrate of PAD4 induced deimination in
neutrophils. We identified deimination at Arg 53, a residue reported to interact with
DNA. Future studies on the effect of deimination on interactions linker histones and
linker DNA will be important in elucidating the mechanism of NET formation.
A related role of deimination in loosening chromatin might be seen while
transmigration of neutrophils to the site of inflammation. Neutrophil influx into inflamed
sites is preceded by rolling, adhesion to vessel endothelium and then diapedesis through
the cell junctions (396). The ability of neutrophils to squeeze themselves through tight
junctions of endothelium requires highly plastic nuclei. One possible way to achieve this
is by deiminating histones so as to loosen chromatin. The fact that arthritic joints of RA
patients are infiltrated with neutrophils (397) and that neutrophils of RA patients show
high expression of PAD4 mRNA (228) support this thought. It is possible that increased
PAD4 activity allows for increased neutrophil infiltration in joints of RA susceptible
individuals and cause increased inflammation in response to even minor trauma.
Whether this is true could be ascertained by in vitro transmigration experiments with
human donor neutrophil in presence of PAD4 inhibitors or by comparing neutrophil
influx after inducing sterile peritonitis in PAD4 deficient and control mice. Presently,
neutrophils are known to deiminate histone to make NETs in response to inflammatory
stimuli (202). If deimination indeed helps in transmigration of neutrophils then an
important question will be to identify a stimulus that induces just sufficient deimination
of histones in neutrophils that facilitates transmigration and yet allows normal neutrophil
function rather than NET formation. Other interesting questions like what role do
deiminated histones play in NETs needs to be investigated in future. Recently, NETs and
excess of histones have been shown to promote thrombosis (307). What role deimination
plays in increasing thrombosis has not been investigated. As deiminated histones are
released during neutrophil activation, it is important to investigate how they interact with
other self-proteins.
Numerous reports of autoimmune responses against deiminated non-nuclear
proteins have strengthened the notion that deimination, a PTM that accompanies
inflammation or differentiation, might lead to autoimmunity by generating ‘neoepitopes”. In our attempt to understand the contribution of deimination in promoting
autoimmunity we found that autoimmune responses against deiminated histones occur
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rarely. Screening of sera from FS SLE, RA, SS, Scl and ANCA vasculides patients
revealed that only FS patients have anti-deiminated histone autoantibodies. Other studies
have pointed to increased levels PAD4 enzyme and deiminated proteins in RA. Also,
SLE patients have preponderance of anti-histone autoantibodies and lupus pathogenesis
promotes neutrophil activation and NET formation. Still, our results show that the sera
from SLE, RA and many other autoimmune patients do not prefer deiminated histones.
Consistent with human studies, sera of autoimmune lupus prone mice preferred nondeiminated histones. While deimination promotes antigen recognition for many nonnuclear proteins, the rarity of autoantibodies against deiminated histones suggests that
development of autoimmune responses against important nuclear antigens is protected.
As FS is considered to be a severe variant of RA, the work in this dissertation
opens up several interesting questions relevant to understanding of autoimmune process
in FS and RA. Studies to identify RA patients at risk of developing FS will help in
understanding autoimmune responses against deiminated histones. Our results show
robust tolerance to deiminated histones in RA and SLE patients as well as lupus prone
mice. Future studies might identify mechanisms of tolerance to deiminated histones
which can be applied to modulate autoimmune response against other autoantigens. Our
current study also provides opportunities to further investigate neutrophil function of
transmigration and NETosis, so that these important mechanisms involved in innate
defense can be understood better. Detailed understanding of neutrophil function in health
and disease is required to devise better strategies for fighting infections while preventing
potential adverse consequences of uncontrolled neutrophils activation such as thrombosis,
sepsis and autoimmunity.
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